Site-specific antibody-drug conjugates and methods of use

By employing CD38 molecules fused at the antibody C-termini for site-specific conjugation, the ADCs achieve higher DARs and improved stability, effectively targeting and suppressing prostate tumors.

WO2026241378A1PCT designated stage Publication Date: 2026-11-19UNIV OF SOUTHERN CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027975
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) lack the necessary potency and specificity for effective cancer treatment, as they often rely on non-specific conjugation methods that result in unstable and less active therapeutic agents.

Method used

The development of antibody-drug conjugates (ADCs) with defined drug-to-antibody ratios (DARs) achieved through a single-step conjugation of bifunctional antibody-CD38 fusion proteins with designer dinucleotide-based covalent inhibitors, specifically targeting human prostate-specific membrane antigen (PSMA) using CD38 molecules fused at the antibody C-termini.

Benefits of technology

The resulting ARC-ADCs exhibit enhanced stability and potency against PSMA-expressing prostate cancer cells both in vitro and in vivo, demonstrating feasibility for effective cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027975_19112026_PF_FP_ABST
    Figure US2026027975_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Site-specifically conjugated ADCs with greater drug-to-antibody ratios (DARs), monoclonal antibodies targeting prostate-specific membrane antigens (PSMA) genetically fused with tandem CD38 enzymes. The resulting antibody-CD38 fusions coupled with its dinucleotide substrate-derived drug linker facilitate generation of ADP-ribosyl cyclase-enable ADCs (ARC-ADCs) carrying 2, 4, 6, and 8 tubulin inhibitors. In vitro and in vivo studies indicated highly potent and selective cytotoxicity against human PSMA-expressing prostate cancer cells for the anti-PSMA ARC-ADC with a DAR of 6.
Need to check novelty before this filing date? Find Prior Art

Description

DESCRIPTIONSITE-SPECIFIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USEREFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of United States Provisional Patent Application No. 63 / 804,896, filed May 13, 2025, the entirety of which is incorporated herein by reference.STATEMENT OF FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under Grant Nos. R35GM137901, R01EB031830, and R01CA276240 awarded by the National Institutes of Health. The government has certain rights in the invention,REFERENCE TO A SEQUENCE LISTING

[0003] This application contains a Sequence Listing XML, which has been submitted electronically and is⁻¹ereby incorporated by reference in its entirety. Said Sequence Listing XML, created on May 12, 2026, is named USCAP0025WO.xml and is 26,286 bytes in size.BACKGROUND1. Field

[0004] The present disclosure relates generally to the fields of medicine and immunotherapy. More particularly, it concerns ADCs that have enhanced potency and selective cytotoxicity, and methods of their use.2, Description of Related Art

[0005] Unlike conventional chemotherapeutics lacking tissue specificity, antibody¬ drug conjugates (ADCs) resulted from chemical conjugations of small-molecule drugs to monoclonal antibodies permit selective delivery of the therapeutic agents to target cells. ADC- assisted drug delivery requires recognition of disease-associated antigens by the antibody component and subsequent internalization of the whole conjugate, followed by release of effector molecules. Due to high affinity and specificity of the targeting antibodies as well as strong potency of the payloads, ADCs exhibit remarkable efficacy coupled with reduced14903-1524-0106, v. 1toxicity in the clinic, gaining considerable interests in expanding utility and improving pharmacological properties of this therapeutic modality (Beck, et al., 2017; Fu, et al., 2022; Liu, et al., 2016; Samantasinghar, et al., 2023; Dumontet, et al., 2023; Zhang, et al., 2015; Dai. et al., 2020; Yao, et al., 2021; Lambert, et al,, 2017).

[0006] Various types of approaches⁻¹ave been established to generate heterogeneous and homogeneous ADC through conjugating small-molecule drugs to antibodies in a random and site-specific fashion, respectively(Axup, et al., 2012; Beerli, et al., 2015; Bruins, et al., 2017; Li, et al., 2017; Lin, et al., 2017; NannA, et ah, 2017; Dai, et al., 2020; Dai, et al., 2021; Okeley, et al., 2013; Wakankar, et al., 2010; Zhu, et al., 2014; Shi, et al., 2020; VanBrunt, et al., 2015; Kim, et al., 2024; Hwang, et al., 2020) In contrast to the non-specific conjugation methods, attachments of payloads at selective positions tend to result in ADC products with enhanced stabilities and / or activities (Junutula, et al., 2008). However, ADC with higher potency are needed.SUMMARY

[0007] Antibody-drug conjugates (ADCs) uniquely allow cell-specific delivery of nonselective small-molecule drugs, resulting in significantly improved therapeutic index. Given their outstanding potency and specificity, ADCs⁻¹ave been emerging as an increasingly important class of therapeutics. Provided herein are CD38 molecules tandemly fused at antibody C -termini that retain their enzymatic activities to facilitate generation of ARC- ADCs with greater DARs. This was achieved through coupling bifunctional antibody-CD38 fusion proteins with designer dinucleotide-based covalent inhibitors with stably attached payloads. The resulting ARC-ADC with a defined drug-to-antibody ratio (DAR) of 6 can be rapidly generated through a single-step conjugation step. The exemplary ARC-ADC targeting human prostate-specific membrane antigen (PSMA) display excellent stability and potency against PSMA-expressing prostate cancer both in vitro and in vivo. This work demonstrates feasibility of generating ARC-ADCs with larger DARs through tandem CD38 fusions and provides therapeutic candidates for prostate cancer treatment.

[0008] Accordingly, provided herein are antibody-drug conjugates comprising a fusion protein of an antibody covalently linked to an / XDP-ribosyl cyclase protein via a linker moiety; a 2’-modified araNAD4analogue or a 2’-modified araNMN analogue; and a payload wherein the 2’-modified araNAD4analogue or the 2’-modified araNMN analogue is conjugated to the24903-1524-0106, v. 1payload to form a functionalized payload, and the functionalized payload is conjugated to the ADP-ribosyl cyclase protein.

[0009] Preferably, the 2’-modified araNAD+ analogue comprises 2’-X-araNAD-N3, where X is a fluorine atom, a chlorine atom, or a bromine atom, and the 2’-modified araNMN analogue comprises 2’-X-araNMN-PCU, where X is a fluorine atom, a chlorine atom, or a bromine atom.

[0010] The functionalized payload may comprise a 2’-modified araNAD+analogue¬ payload or a 2’ -modified araNMN analogue-payload having a structure disclosed in FIG. 1.

[0011] The antibody may comprise a monoclonal antibody, polyclonal antibody, a single chain Fv, a bispecific antibody, a multispecific antibody, a Fv fragment, a Fab fragment, or a F(ab)2 fragment.

[0012] The ADP-ribosyl cyclase protein may be covalently linked to at least one of the N-terminus or a C-terminus of one or more of the heavy chains or one or more of the light chains of the antibody. The ADP-ribosyl cyclase protein may be covalently linked to the C-terminus of both heavy chains of the antibody or both light chains of the antibody. The ADP- ribosyl cyclase protein may be covalently linked to the C-terminus of both heavy chains and both light chains of the antibody. Preferably, the drug-to-antibody ratio (D R) is 6:1.

[0013] The 2’-modified araNAD+ analogue or the 2’-modified araNMN analogue may be conjugated to glutamate 226 of the catalytic domain of CD38.

[0014] Also provided herein are methods of preparing an antibody-drug conjugate comprising the steps of providing an antibody-linker-ADP -ribosyl cyclase fusion protein, combining a 2’-modified araNADhanalogue or a 2’ -modified araNMN analogue and a payload moiety to form a X -modified araNAD+analogue-payload or a 2’ -modified araNMN analogue¬ payload, and conjugating the antibody -linker- ADP-ribosyl cyclase fusion protein to the 2’-modified araN AD+analogue-payload or the 2’-modified araNMN analogue-payload to form an antibody-drug conjugate.

[0015] The payload may be a tubulin inhibitor, preferably MMAF.

[0016] Also provided herein are methods of treating cancer comprising administering to a subject having cancer or suspected of having cancer a therapeutically effective amount of34903-1524-0106, v. 1any of the antibody-drug conjugates disclosed herein, thereby inhibiting the growth of cancer cells or killing cancer cells and treating the cancer.

[0017] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF DRAWINGS

[0018] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0019] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0020] FIGS. 1A-1B. Design and synthesis of anti-PSM / X ARC-ADCs with varied DARs. (FIG. 1A) Schematic of generation of site-specific anti-PSMA ARC-ADCs for targeting prostate cancer cells. (FIG. IB) Coomassie blue-stained SDS-PAGE gels for purified anti-PSMA IgG and IgG-CD38 fusion proteins, indicating nonreducing conditions and “+” indicating reducing conditions.

[0021] FIGS. 2A-2E. Characterization of anti-PSMA IgG-CD38 fusions. (FIG. 2 A) ADP -ribosyl cyclase activities of the fused CD38 molecules. IgG or IgG-CD38 fusion (10 nM) was incubated with 100 pM NGD+in PBS to monitor ADP-ribosyl cyclase activities by measuring formation of fluorescent cyclic GDP-ribose at 410 nm. Recombinant CD38 extracellular domain (20 nM) was included as positive controls. (FIG. 2B) ELISA analysis of binding of IgG-CD38 fusion or CD38 to human PSMA. Anti-PSMA IgG was included as positive controls. (FIG. 2C) Flow cytometry of PSMA expression on human LNCaP, C4-2B, and DU145 cells. (FIG. 2D) and (FIG. 2E) Flow cytometric analysis of binding of IgG and44903-1524-0106, v. 1IgG-CD38 fusions (FIG. 2D) and recombinant CD38 (FIG. 2E) to LNCaP, C4-2B, and DU145 cells.

[0022] FIGS. 3A-3C. In vitro cytotoxicity of anti-PSMA ARC-ADCs Prostate cancer cell lines LNCaP (FIG. 3A), C4-2B (FIG. 3B), and DU145 (FIG. 3C) were used to incubate with ARC-ADCs at various concentrations for 72 h. Free drug (MMAF-alkyne), MMAF -linker conjugate, and anti-PSMA IgG were included as controls. Cell viabilities were determined by MTT assays.

[0023] FIGS. 4A-4E. Pharmacokinetics and pharmacodynamics of anti-PSMA ARC- ADCs in mice. (FIG. 4A) Pharmacokinetics of surrogate anti-PSMA ARC-ADCs with FITC as payloads in mice. (FIG. 4B) In vivo efficacy of anti-PSMA ARC-ADCs in a mouse xenograft model of prostate cancer. Male NSG mice (n=5) with subcutaneously implanted LNCaP cells were treated with PBS vehicle or ARC-ADCs via intravenous injections (black arrows) every' other day for four times. (FIG. 4C) Kaplan-Meier survival curves for PBS- and anti-PSMA ARC -ADC -treated groups. (FIG. 4D) Body weights of mice during the efficacy study. (FIG.4E) and (FIG. 4F) ALT activities (FIG. 4E) and creatinine concentrations (FIG. 4F) in mouse plasma on day 24 after the start of treatment.

[0024] FIGS. 5A-5E. Mass spectra of light chain (LC) and heavy chain (HC) for anti- PSMA IgG-CD38 fusions and ARC-ADCs. (FIG. 5 A) IgG-2CD38 fusion and DAR2-ARC- ADC. (FIG 5B) IgG-4CD38-S fusion and DAR4S-ARC-ADC. (FIG. 5C) IgG-4CD38-D fusion and DAR4D-ARC-ADC. (FIG. 5D) IgG-6CD38 fusion and DAR6-ARC-ADC. (FIG.5E) IgG-8CD38 fusion and DAR8-ARC-ADC.

[0025] FIGS. 6A-6B. Flow cytometric analysis of binding of anti-PSMA ARC-ADCs to prostate cancer cells. (FIG. 6A) Binding of ARC-ADCs to human LNCaP, C4-2B, and DU145 cells. IgG-CD38 fusions were included for comparison. (FIG. 6B) Binding of recombinant CD38 and CD38-MMAF conjugate to LNCaP, C4-2B, and DUI45 cells. Anti- PSMA IgG was included as positive controls.

[0026] FIG. 7. Ratios of major organ weights to body weights of mice at the end of efficacy study.54903-1524-0106, v. 1

[0027] FIG. 8. Gel filtration chromatography of anti-PSMA IgG constructs. Peak A is quantified as the related level of aggregation of different constructs. Peak B shows the monomer of each anti-PSMA IgG construct.

[0028] FIG. 9. Protein thermal stability for anti-PSMA IgG constructs. Melting temperature (Tm) for each construct was calculated.DETAILED DESCRIPTION

[0029] Antibodies with genetically fused CD38 enzymatic domains at C -termini of heavy and / or light chain can be facilely attached with cytotoxic drugs via a 2'-Cl-substituted nicotinamide adenine dinucleotide (NAD+) linker (Dai, et al., 2021). As a covalent inhibitor of CD38, this synthetic drug linker carrying payloads can rapidly react with the glutamate 226 (E226) residue at the CD38 catalytic site, resulting in stable, site-specific ADP-ribosyl cyclase- enabled ADCs (ARC-ADCs) with DARs of 2 and 4 (Dai, et al., 2020; Dai, et al., 2021).

[0030] To further increase the DARs of ARC-ADCs for potentially improved efficacy, additionally fused CD38 domains would be needed. As N-terminal fusion of CD38 affects antibody binding affinity (Dai, et al., 2020), the inventors⁻¹ypothesized that tandemly fused CD38 molecules at antibody C -termini may retain their enzymatic activities to facilitate generation of ARC-ADCs with greater DARs. To test this, a monoclonal antibody against human prostate-specific membrane antigen (PSMA) was attempted for genetic fusions of single and dual tandem CD38 with C -termini of heavy and light chains. PSMA is frequently overexpressed in prostate cancer cells (Liu, et al., 2008; Troyer, et al., 1995). Therapies targeting PSMA have been approved for treatment of patients with prostate cancer (Jang, et al., 2023; Capasso, et al., 2024). In the studies described herein, anti-PSMA ARC-ADCs with DARs of 2, 4, 6, and 8 were successfully synthesized by site-specifically conjugating the tubulin inhibitor monomethyl auristatin F (MMAF) via the 2'-Cl -arabinose NAD+ drug linker to the anti-PSMA immunoglobulin G (IgG) with C -terminal single and dual tandem CD38 fusions (FIG. 1A). Anti-PSMA ARC-ADCs with higher DARs exhibit increased in vitro cytotoxicity for PSMA-expressing prostate cancer cells. The anti-PSMA ARC-ADC with six MMAF molecules can markedly suppress growth of prostate tumors in a mouse xenograft model.

[0031] This work advances the site-specific? XDC technology toward increased amounts of payloads for enhanced potency. By tandemly fusing CD38 enzymatic domains to64903-1524-0106, v. 1C -termini of the heavy and / or light chain of an antibody, additional conjugation sites can be created within antibody-CD38 fusions, allowing one-step facile synthesis of ARC-ADCs with DARs of 4, 6, and 8, preferably 6. Despite for the lack of free N- and C-terminus, the internally fused CD38 domain remains active to catalyze covalent attachment of the drug-linker conjugate. This tandem strategy for adding CD38 at antibody C-terminus proves feasible for producing anti-PSMA ARC-ADCs with higher DARs and potent in vitro and in vivo activities. Using this approach, antibodies with varied numbers and locations of fused CD38 can be generated for synthesizing homogeneous ADCs with potentially improved pharmacological properties.

[0032] In vitro cytotoxicity assays indicated stronger potency for anti-PSMA ARC-ADCs with higher DARs except for DAR8-ARC-ADC, possibly due to decreased binding affinity to PSMA antigen. The tandemly fused CD38 molecules on both HC and LC of DAR8-ARC-ADC may alter their pairing, resulting in conformational changes in the antigen-binding site. Among the five constructed anti-PSMA IgG-CD38 fusions, the expression yield is reduced with an increase in the number of fused CD38. And the yield of IgG-4CD38-S is⁻¹igher than that of IgG-4CD38-D. These suggest destabilization of the immunoglobulin scaffold by the additions of CD38 and reduced stability for the IgG fusion with tandemly fused CD38 relative to one with single CD38 on heavy and light chains. To improve stability and / or affinity of antibody-CD38 fusions, the impact of CD38 on antibody structure and function may be minimized by reducing its size while retaining catalytic activity. Additionally, various forms of linkers between functional domains may be tested to optimize physicochemical and pharmacological properties of antibody-CD38 fusion proteins for ADCs production.

[0033] In addition to fusing additional CD38 molecules, the NAD+-based drug linker may be modified to cany extra copies of payloads for enhancing D ARs of ARC-ADCs. Other types of cytotoxic agents may also be covalently attached for targeted delivery by / XRC-ADCs. The efficacy and safety profiles of the generated anti-PSMA ARC-ADCs need to be further assessed using different animal models. Importantly, this approach can be readily extended to develop site-specific ADCs targeting other tumor-associated antigens for potential cancer treatment.

[0034] Anti-PSMA ARC-ADCs with greater DARs were synthesized by tandemly fusing CD38 catalytic domains to antibody C-termini. DAR6-ARC-ADC can selectively kill74903-1524-0106, v. 1PSMA-positive prostate cancer cells with marked potency and effectively suppress growth of established prostate tumors in mice, offering an ADC candidate for targeted therapy.I. Definitions

[0035] “Nucleic acid,” “nucleic acid sequence,” “oligonucleotide,” “polynucleotide” or other grammatical equivalents as used herein means at least two nucleotides, either deoxyribonucleotides or ribonucleotides, or analogs thereof, covalently linked together. Polynucleotides are polymers of any length, including, e.g., 20, 50, 100, 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A polynucleotide described herein generally contains phosphodi ester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, cRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also includes both double- and single-stranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule. Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be84903-1524-0106, v. 1achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0036] The ter s “peptide,” “polypeptide” and “protein” used herein refer to polymers of amino acid residues. These terms also apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers. In the present case, the term “polypeptide” encompasses an antibody or a fragment thereof.

[0037] The term “contacting” refers to the act of touching, making contact, or of bringing to immediate or close proximity, including at the cellular or molecular level, for example, to bring about a physiological reaction, a chemical reaction, or a physical change, e.g., in a solution, in a reaction mixture, in vitro, or in vivo.

[0038] An “effective amount” refers to an amount effective to treat a disease, disorder, and / or condition, or to bring about a recited effect. For example, an effective amount can be an amount effective to reduce the progression or severity of the condition or symptoms being treated. Determination of a therapeutically effective amount is well within the capacity of persons skilled in the art. The term “effective amount” is intended to include an amount of a compound described herein, or an amount of a combination of compounds described herein, e.g., that is effective to treat or prevent a disease or disorder, or to treat the symptoms of the disease or disorder, in a host. Thus, an “effective amount” generally means an amount that provides the desired effect. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.

[0039] The terms “treating,” “treat,” and “treatment” include (i) preventing a disease, pathologic or medical condition from occurring (e.g., prophylaxis); (ii) inhibiting the disease, pathologic or medical condition or arresting its development; (iii) relieving the disease, pathologic or medical condition; and / or (iv) diminishing symptoms associated with the disease, pathologic or medical condition. Thus, the terms “treat,” “treatment,” and “treating” can extend to prophylaxis and can include prevent, prevention, preventing, lowering, stopping or reversing the progression or severity of the condition or symptoms being treated. As such, the term “treatment” can include medical, therapeutic, and / or prophylactic administration, as appropriate.94903-1524-0106, v. 1

[0040] The terms “inhibit,” “inhibiting,” and “inhibition” refer to the slowing, halting, or reversing the growth or progression of a disease, infection, condition, or group of cells. The inhibition can be greater than about 20%, 40%, 60%, 80%, 90%, 95%, or 99%, for example, compared to the growth or progression that occurs in the absence of the treatment or contacting.

[0041] As used herein, “fused” means to couple directly or indirectly one molecule with another by whatever means, e.g., by covalent bonding, by non-covalent bonding, by ionic bonding, or by non-ionic bonding. Covalent bonding includes bonding by various linkers such as thioether linkers or thioester linkers. Direct fusion involves one molecule attached to the molecule of interest.

[0042] By the term “specifically binds,” as used herein, is meant a molecule, such as an antibody, which recognizes and binds to another molecule or feature, but does not substantially recognize or bind other molecules or features in a sample.

[0043] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specifi ed component has been purposefully formulated into a composition and / or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.

[0044] As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.

[0045] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” As used herein “another” may mean at least a second or more.

[0046] Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the inherent variation in the method being employed to determine the value, the variation that exists among the study subjects, or a value that is within 10% of a stated value.104903-1524-0106, v. 1II. Antibodies and Modifications of Antibodies

[0047] An antibody may bind to an antigen or epitope of an antigen expressed on a cancer or malignant cell. Examples of cancers treatable by the invention disclosed herein include, but are not limited to, lung cancer, breast cancer, ovarian cancer, cervical cancer, gastrointestinal cancers, head and neck cancer, melanoma, sarcoma, esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm, renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage IIIA skin melanoma; stage IIIB skin melanoma, stage IIIC skin melanoma; stage IV skin melanoma, malignant melanoma of head and neck, lung cancer, non-small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, richter's syndrome; waldenstrom macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent ewing sarcoma / peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma; metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma; stage III merkel cell carcinoma; stage IV merkel ceil carcinoma, myelodysplastic syndrome and Sezary syndrome. The solid tumor may be a non-lymphoma solid tumor. The solid tumor may be multiple myeloma.

[0048] Exemplary antigens that may be targeted with an antibody used with the invention may include, but is not limited to, carbonic anhydrase IX, B7, CCCL19, CCCL21, CXCR4, CLL-1, CSAp, HER-2 / neu, BrE3, GDI, CDla, CD2, CD3, CD4, CD5, CD8, CD11 A,114903-1524-0106, v. 1CD14, CD15, CD16, CD18, CD19, CD20 (e.g., C2B8, hA20, 1F5 MAbs), CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD44, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD 126, CD 133, CD 138, CD 147, CD 154, CEACAM5, CEACAM6, CTLA-4, alphafetoprotein (AFP), VEGF, ED-B fibronectin (e.g., L19), EGP-I (TROP-2), EGP-2 (e.g., 17- 1A), EGF receptor (ErbBl), ErbB2, ErbB3, Factor H, FHL-1, Flt-3, folate receptor, Ga 733, GRO-P, HMGB-1, hypoxia inducible factor (HIF), insulin-like growth factor (ILGF), IFN-y, IFN-a, IFN-P, IFN-k, IL-2R, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL- 8, IL- 12, IL- 15, IL-17, IL-18, IL-25, IP-10, IGF-1 R, la, I IM 1.24, gangliosides, I ICG, the HLA-DR antigen to which L243 binds, CD66 antigens, i.e., CD66a-d or a combination thereof, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, macrophage migration-inhibitory factor (MIF), MUC1, MUC2, MUC3, MUC4, MUC5ac, placental growth factor (P1GF), PSA (prostatespecific antigen), PSMA, PAM4 antigen, PD-L1 receptor, NCA-95, NCA-90, A3, A33, Ep-CAM, KS-1, Le(y), mesothelin, 5100, tenascin, TAC, Tn antigen, Thomas-Friedenreich antigens, tumor necrosis antigens, tumor angiogenesis antigens, TNF-a, TRAIL receptor (R1 and R2), TROP-2, VEGFR, RANTES, T101, as well as cancer stem cell antigens, complement factors C3, C3a, C3b, C5a, C5, and an oncogene product. These antigens also include the human, murine, porcine, or bovine homologs as applicable. Preferably, the antigen is HER2 or CLL-1. Methods of making antibodies to bind specific antigens are well known in the art, for example, as disclosed in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Springs Harbor Laboratory' Press, Cold Spring Harbor, N. Y. (1988); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989).

[0049] An “antibody” is an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact polyclonal or monoclonal antibodies, but also fragments thereof (such as Fab, Fab', F(ab')2, Fv, Fd, Fd', single chain antibody (ScFv), diabody, linear antibody), mutants thereof, naturally occurring variants, fusion proteins comprising an antibody portion with an antigen recognition site of the required specificity, chimeric antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity.124903-1524-0106, v. 1

[0050] Th term “CD38” refers to a 46 kDa type II transmembrane glycoprotein (UniProtKB: P28907; Accession No, NM_001775.4). It has a short N-terminal cytoplasmic tail of 20 amino acids, a single transmembrane helix and a long extracellular domain of 256 amino acids. It is expressed on the surface of many immune cells including CD4 and CD8 positive T cells, B cells, NK cells, monocytes, plasma cells and on a significant proportion of normal bone marrow precursor cells. In some instances, the expression of CD38 in lymphocytes may be dependent on the differentiation and activation state of the cell, for example, resting T and B cells may be negative while immature and activated lymphocytes may be predominantly positive for CD38 expression, CD38 mRNA expression has been detected in non-hemopoeitic organs such as the pancreas, brain, spleen and liver (Koguma, T. (1994) Biochim. Biophys. Acta 1223:160).

[0051] CD38 is a multifunctional ectoenzyme that is involved in transmembrane signaling and cell adhesion. It is also known as cyclic ADP ribose hydrolase because it can transform NAD+and NADP into cADPR, ADPR and NAADP, depending on extracellular pH. These products induce Ca2+-mobilization inside the cell, which can lead to tyrosine phosphorylation and activation of the cell. CD38 is also a receptor that can interact with a ligand, CD3I. Activation of receptor via CD31 leads to intracellular events including Ca2+mobilization, cell activation, proliferation, differentiation and migration. The extracellular / catalytic domain of CD38 may include the following mutations: (N100D, N164A, N129D, andN209D).

[0052] An ‘’isolated antibody” is one that has been separated and / or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In particular instances, the antibody is purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most particularly more than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator; or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or silver stain. An isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody’s natural environment will not be present. Ordinarily, however, an isolated antibody will be prepared by at least one purification step.134903-1524-0106, v. 1

[0053] The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. The term “heavy chain” as used herein refers to the larger immunoglobulin subunit which associates, through its amino terminal region, with the i munoglobulin light chain. The heavy chain comprises a variable region (VH) and a constant region (CH). The constant region further comprises the CHI, hinge, CH2, and CH3 domains. In the case of IgE, IgM, and IgY, the heavy chain comprises a CH4 domain but does not have a hinge domain. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (y, u. a, 8, s), with some subclasses among them (e.g., yl-y4, al-a2). It is the nature of this chain that determines the “class” of the antibody as IgG, IgM, IgA IgD, or IgE, respectively. The immunoglobulin subclasses (isotypes), e.g., IgGI, IgG2, IgG3, IgG4, IgAl, etc. are well characterized and are known to confer functional specialization.

[0054] The term “light chain” as used herein refers to the smaller immunoglobulin subunit which associates with the amino terminal region of a heavy chain. As with a heavy chain, a light chain comprises a variable region (VL) and a constant region (CL). Light chains are classified as either kappa or lambda (K, X) based on the amino acid sequences of their constant domains (CL). A pair of these can associate with a pair of any of the various⁻¹eavy chains to form an immunoglobulin molecule. Also encompassed in the meaning of light chain are light chains with a lambda variable region (V-lambda) linked to a kappa constant region (C-kappa) or a kappa variable region (V-kappa) linked to a lambda constant region (C -lambda).

[0055] An IgM antibody, for example, consists of 5 basic heterotetramer units along with an additional polypeptide called J chain, and therefore contain 10 antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages comprising 2-5 of the basic 4-chain units along with J chain. In the case of IgG s, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable region (VH) followed by three constant domains (CH) for each of the alpha and gamma chains and four CH domains for mu and isotypes. Each L chain has at the N-terminus, a variable region (VL) followed by a constant domain (CL) at its other end. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CHI). Particular amino acid residues are believed to form an144903-1524-0106, v. 1interface between the light chain and heavy chain variable regions. The pairing of a VH and VL together forms a single antigen-binding site. For the structure and properties of the different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G Parslow (eds.), Appleton & Lange, Norwalk, Conn., 1994, page 71, and Chapter 6.

[0056] A “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. The term “variable” refers to the fact that certain segments of the variable regions differ extensively in sequence among antibodies. The variable regions of both the light (VL) and heavy (VII) chain portions mediate antigen binding and define the specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the entirety of the variable regions. Instead, the variable regions consist of relatively invariant stretches called framework regions (FRs) separated by shorter regions of extreme variability called complementarity determining regions (CDRs) or hypervariable regions. The variable regions of native heavy and light chains each comprise four FRs, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs complement an antigen’s shape and determine the antibody’s affinity and specificity for the antigen. There are six CDRs in both VL and VH. The CDRs in each chain are held together in close proximity by the FRs and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Sth Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0057] The term “hypervariable region” when used herein refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues from a “complementarity determining region” or “CDR” (e.g., around about residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the VL, and around about 31-35 (Hl ), 50-65 (H2) and 95-102 (H3) in the VH when numbered in accordance with the Kabat numbering system; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)); and / or those residues from a “hypervariable loop” (e.g., residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the VL, and 26-32 (Hl), 52-56 (H2) and 95-101 (H3) in the VH when numbered in accordance with the Chothia numbering system; Chothia and Lesk, J. Mol. Biol. 196:901-154903-1524-0106, v. 1917 (1987)); and / or those residues from a “hypervariable loop’VCDR (e.g., residues 27-38 (LI), 56-65 (L2) and 105-120 (L3) in the VL, and 27-38 (Hl), 56-65 (H2) and 105-120 (H3) in the VH when numbered in accordance with the IMGT numbering system; Lefranc, M. P. et al. Nucl. Acids Res, 27:209-212 (1999), Ruiz, M. et al. Nucl. Acids Res. 28:219-221 (2000)). Optionally the antibody has symmetrical insertions at one or more of the following points 28, 36 (LI), 63, 74-75 (L2) and 123 (L3) in the AT, and 28, 36 (Hl), 63, 74-75 (H2) and 123 (H3) in the VsubH when numbered in accordance with AHo; Honneger, A. and Plunkthun, A. J. Mol. Biol. 309:657-670 (2001)). As used herein, a CDR may refer to CDRs defined by any of these numbering approaches or by a combination of approaches or by other desirable approaches. In addition, a new definition of highly conserved core, boundary and hyper- variable regions can be used.

[0058] A “constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination. The constant regions of the light chain (CL) and the heavy chain (CHI, CH2 or CH3, or CH4 in the case of IgM and IgE) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen binding site or amino-terminus of the antibody. The constant regions are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody dependent cellular cytotoxicity (ADCC), antibody¬ dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and antibody-dependent complement deposition (ADCD).

[0059] For example, an antibody or antibody fragment may have a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgGl, IgG2, IgG3, and IgG4. The antibody or antibody fragment may have a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda. The constant region may be altered, e.g., mutated, to modify the properties of the antibody or antibody fragment (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and / or complement function). The antibody or antibody fragment may not recruit effector cells or fix complement. The antibody or antibody fragment may have reduced or no ability to bind an Fc164903-1524-0106, v. 1receptor. For example, it is an isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

[0060] The constant region of the heavy chain of the antibody or antibody fragment may be a human IgGl isotype, having an amino acid sequence:AS TKGPS VFPLAPS SKS T S GGTAALGCLVKDYFPE PVTVS WNS GALT S GVHT FPAVLQS SSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1 )[006 i ] The human IgGl constant region may be modified at amino acid Asn297 (boxed in SEQ ID NO: 1 in the preceding paragraph) to prevent glycosylation of the antibody, for example Asn297Ala (N297A). The constant region of the antibody may be modified at amino acid Leu235 (boxed in SEQ ID NO: 1 in the preceding paragraph) to alter Fc receptor interactions, for example Leu235Glu (L235E) or Leu235Ala (L235A). The constant region of the antibody may be modified at amino acid Leu234 (boxed in SEQ ID NO: I in the preceding paragraph) to alter Fc receptor interactions, e.g., Leu234Ala (L234A). The constant region of the antibody may be altered at both amino acid 234 and 235, for example Leu234Ala and Leu235Ala (L234A / L235A). The constant region of the antibody may be modified at amino acid Gly237 (boxed in SEQ ID NO: 1 in the preceding paragraph) to alter Fc receptor interactions, for example Gly237? Ma (G237A). The constant region of the antibody may be altered at amino acids 234, 234, and 237 for example, Leu234Ala, Leu235Ala, and Gly237Ala (L234A / L235A / G237A). AH residue numbers are according to EU numbering (Kabat, E. A., et al. (1991) SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, FIFTH EDITION, U. S. Department of Health and Human Services, NIH Publication No. 91-3242).

[0062] The constant region of the heavy chain of the antibody may be a human IgG l isotype, having an amino acid sequence:AS TKGPS VFPLAPS SKS T S GGTAALGCLVKDYFPE PVTVS WNS GALT S GVHT FPAVLQS S174903-1524-0106, v. 1STYRWSVLTVLHQDV'JLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQYSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 2)

[0063] The human IgGl constant region may be modified at amino acid? Xsn297 (boxed in SEQ ID NO: 2 in the preceding paragraph) to prevent glycosylation of the antibody, for example Asn297Ala (N297A). The constant region of the antibody may be modified at amino acid Leu235 (boxed in SEQ ID NO: 2 in the preceding paragraph) to alter Fc receptor interactions, for example Leu235Glu (L235E) or Leu235Ala (L235 A). The constant region of the antibody may be modified at amino acid Leu234 (boxed in SEQ ID NO: 2 in the preceding paragraph) to alter Fc receptor interactions, e.g., Leu234Ala (L234A). The constant region of the antibody may be altered at both amino acid 234 and 235, for example Leu234Ala and Leu235Ala (L234A / L235A). The constant region of the antibody may be modified at amino acid Gly237 (boxed in SEQ ID NO: 2 in the preceding paragraph) to alter Fc receptor interactions, for example Gly237Ala (G237A). The constant region of the antibody may be altered at amino acids 234, 234, and 237 for example, Leu234Ala, Leu235Ala, and Gly237Ala (L234A / L235A / G237A). All residue numbers are according to EU numbering (Kabat, E. A., et al., supra).

[0064] The constant region of the heavy chain of the antibody may be a human IgGl isotype, e.g., an allotype of the human IgGl isotype, e.g., the IgGl Glm3 allotype. Exemplary’ human IgGl allotypes are described in Magdelaine-Beuzelin et al. (2009) PHARMACOGENET. GENOMICS 19(5):383-7.

[0065] The constant region of the heavy chain of the antibody may be a human IgG2 isotype, having an amino acid sequence:ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSWTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFN|STFR WSVLTWHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 3)

[0066] The human IgG2 constant region may be modified at amino acid Asn297 (boxed in SEQ ID NO: 3 in the preceding paragraph) to prevent to glycosylation of the antibody, e.g.,184903-1524-0106, v. 1Asn297Ala (N297A), where the residue numbers are according to EU numbering (Kabat, E. A., et al., supra).

[0067] The constant region of the heavy chain of the antibody may be a human IgG3 isotype, having an amino acid sequence:AS TKGPS VFPLAPCSRS T S GGTAALGCLVKDYFPE PVTVS WNS GALT S GVHT FPAVLQS S GLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSC DTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCV'VVDVSHEDPEVQFKWYVDGVE VHNAKTKPREEQY^STFRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCS NIHE ALHN^FTQKSLSLSPGK (SEQ ID NO: 4 )

[0068] The human IgG3 constant region may be modified at amino acid Asn297 (boxed in SEQ ID NO: 4 in the preceding paragraph) to prevent to glycosylation of the antibody, e.g., Asn297Ala (N297A). The human IgG3 constant region may be modified at amino acid Arg435 (boxed in SEQ ID NO: 4 in the preceding paragraph) to extend the half-life, e.g., Arg435H (R435H). All residue numbers are according to EU numbering (Kabat, E. A., et al., supra).

[0069] The constant region of the heavy chain of the antibody may be a human IgG4 isotype, having an amino acid sequence:ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSRWSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG NVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 5)

[0070] The human IgG4 constant region may be modified within the hinge region to prevent or reduce strand exchange, e.g., the human IgG4 constant region is modified at Ser228 (boxed in SEQ ID NO: 5 in the preceding paragraph), e.g., Ser228Pro (S228P). The human IgG4 constant region may be modified at amino acid Leu235 (boxed in SEQ ID NO: 17 in the preceding paragraph) to alter Fc receptor interactions, e.g., Leu235Glu (L235E). The human IgG4 constant region may be modified at both Ser228 and Leu335, e.g., Ser228Pro and194903-1524-0106, v. 1Leu235Glu (S228P / L235E). The human IgG4 constant region may be modified at amino acid Asn297 (boxed in SEQ ID NO. 5 in the preceding paragraph) to prevent to glycosylation of the antibody, e.g., Asn297Ala (N297A). All residue numbers are according to EU numbering (Kabat, E. A., et al., supra).

[0071] The human IgG constant region may be modified to enhance FcRn binding. Examples of Fc mutations that enhance binding to FcRn are Met252Tyr, Ser254Thr, Thr256Glu (M252Y, S254T, T256E, respectively) (DalFAcqua et al. (2006) J. BIOL. CHEM.281(33): 23514-23524), or Met428Leu and Asn434Ser (M428L, N434S) (Zalevsky et al. (2010) NATURE BIOTECH. 28(2): 157-159). All residue numbers are according to EU numbering (Kabat, E. A., et al., supra).

[0072] The constant region of the light chain of the antibody may be a human kappa constant region, e.g., a human kappa constant region having the amino acid sequence:TVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 6)

[0073] The constant region of the light chain of the antibody may be a human kappa constant region, e.g., a human kappa constant region having the amino acid sequence:RTVAAPSVFI FPPSDEQLKSGTAS ’VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSSTLTLSKADYEKHKVYACFFYTHQGLSSPVTKSFNRGEC (SEQ ID NO: 7 )

[0074] The constant region of the light chain of the antibody may be a human lambda constant region, e.g., a human lambda constant region having the amino acid sequence:GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVIKAGVETTKPSKQS NNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC (SEQ ID NO: 8 )

[0075] The antibody may be an antibody fragment. “Antibody fragments” comprise only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen. Examples of antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CHI domains; (ii) the Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CHI domain; (iii) the Fd fragment having VH and CHI domains; (iv) the Fd' fragment having VH and CHI domains and one or more cysteine residues204903-1524-0106, v. 1at the C-terminus of the CH I domain; (v) the Fv fragment having the VL and VH domains of a single antibody; (vi) the dAb fragment which consists of a VH domain; (vii) isolated CDR regions; (viii) F(ab’)2 fragments, a bivalent fragment including two Fab' fragments linked by a disulfide bridge at the hinge region; (ix) single chain antibody molecules (e.g. single chain Fv; scFv); (x) “diabodies” with two antigen binding sites, comprising a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain; (xi ) “linear antibodies” comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary' light chain polypeptides, form a pair of antigen binding regions.

[0076] The antibody may be a chimeric antibody. “Chimeric antibodies” refers to those antibodies wherein one portion of each of the amino acid sequences of heavy and light chains is⁻¹omologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular class, while the remaining segment of the chains is⁻¹omologous to corresponding sequences in another.A. Monoclonal Antibodies

[0077] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they may be synthesized un contaminated by other antibodies. The modifier “monoclonal” is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies useful in the present disclosure may be prepared by the hybridoma methodology first described by Kohler et al., Nature, 256:495 (1975), or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see, e.g., U. S. Pat. No. 4,816,567) after single cell sorting of an antigen specific B cell, an antigen specific plasmablast responding to an infection or immunization, or capture of linked heavy and light chains from single cells in a bulk sorted antigen specific collection. The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991), for example.214903-1524-0106, v. 1

[0078] Methods for producing monoclonal antibodies of various types, including chimeric and fully human, are well known in the art and highly predictable. For example, the following U. S. patents and patent applications provide enabling descriptions of such methods: U. S. Patent Application Nos. 2004 / 0126828 and 2002 / 0172677; and U. S. Pat. Nos. 3,817,837;3,850,752; 3,939,350; 3,996,345; 4,196,265; 4,275,149; 4,277,437; 4,366,241; 4,469,797;4,472,509; 4,606,855; 4,703,003; 4,742,159; 4,767,720; 4,816,567; 4,867,973; 4,938,948;4,946,778; 5,021,236; 5,164,296; 5,196,066; 5,223,409; 5,403,484; 5,420,253; 5,565,332;5,571,698; 5,627,052; 5,656,434; 5,770,376; 5,789,208; 5,821,337; 5,844,091; 5,858,657;5,861,155; 5,871,907; 5,969,108; 6,054,297; 6,165,464; 6,365,157; 6,406,867; 6,709,659;6,709,873; 6,753,407; 6,814,965; 6,849,259; 6,861,572; 6,875,434; and 6,891,024, each incorporated herein by reference.B, Single Chain Antibodies

[0079] A single chain variable fragment (scFv) is a fusion of the variable regions of the heavy and light chains of immunoglobulins, linked together with a short linker. This chimeric molecule retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of a linker peptide. This modification usually leaves the specificity unaltered. scFv can be created directly from subcloned heavy and light chains derived from a hybridoma or B cell. Single chain variable fragments lack the constant Fc region found in complete antibody molecules, and thus, the common binding sites (e.g., protein A / G) used to purify antibodies. These fragments can often be purified / immobilized using Protein L since Protein L interacts with the variable region of kappa light chains.

[0080] Flexible linkers generally are comprised of helix- and turn-promoting amino acid residues such as alanine, serine and glycine. However, other residues can function as well. For example, the linker may have a proline residue two residues after the VH C terminus and an abundance of arginines and prolines at other positions. As another example, the linker may have the sequence of GGRGSGGGGSGSGGS (SEQ ID NO: 9) or GGGGSGGGGSGGGGS (SEQ ID NO: 20).

[0081] A single-chain antibody may also be created by joining receptor light and heavy chains using a non-peptide linker or chemical unit. Generally, the light and heavy chains will be produced in distinct cells, purified, and subsequently linked together in an appropriate fashion (i.e., the N-terminus of the heavy chain being attached to the C-terminus of the light chain via an appropriate chemical bridge).224903-1524-0106, v. 1

[0082] Cross-linking reagents are used to form molecular bridges that tie functional groups of two different molecules, e.g., a stabilizing and coagulating agent. However, it is contemplated that dimers or multimers of the same analog or heteromeric complexes comprised of different analogs can be created. To link two different compounds in a stepwise manner, hetero-bifunctional cross-linkers can be used that eliminate unwanted homopolymer formation

[0083] An exemplary hetero-bifunctional cross-linker contains two reactive groups: one reacting with a primary amine group (e.g., N-hydroxy succinimide) and the other reacting with a thiol group (e.g., pyridyl disulfide, maleimides, halogens, etc.. Through the primary amine reactive group, the cross-linker may react with the lysine residue(s) of one protein (e.g., the selected antibody or fragment) and through the thiol reactive group, the cross-linker, already tied up to the first protein, reacts with the cysteine residue (free sulfhydryl group) of the other protein (e.g., the selective agent).

[0084] It is preferred that a cross-linker having reasonable stability in blood will be employed. Numerous types of disulfide bond-containing linkers are known that can be successfully employed to conjugate targeting and therapeutic / preventative agents. Linkers that contain a disulfide bond that is sterically hindered may prove to give greater stability in vivo, preventing release of the targeting peptide prior to reaching the site of action. These linkers are thus one group of linking agents.

[0085] For example, SMPT is a bifunctional cross-linker containing a disulfide bond that is ‘"sterically hindered” by an adjacent benzene ring and methyl groups. It is believed that steric hindrance of the disulfide bond serves a function of protecting the bond from attack by thiolate anions such as glutathione which can be present in tissues and blood, and thereby help in preventing decoupling of the conjugate prior to the delivery of the attached agent to the target site. The SMPT cross-linking reagent, as with many other known cross-linking reagents, lends the ability to cross-link functional groups such as the SH of cysteine or primary amines (e.g, the epsilon amino group of lysine). Another possible type of cross-linker includes the hetero¬ bifunctional photoreactive phenylazides containing a cleavable disulfide bond such as sulfosuccinimidyl-2-(p-azido salicylamido) ethyl-l,3'-dithiopropionate. The N-hydroxy- succinimidyl group reacts with primary amino groups and the phenylazide (upon photolysis) reacts non-selectively with any amino acid residue.234903-1524-0106, v. 1

[0086] In addition to hindered cross-linkers, non-hindered linkers also can be employed in accordance herewith. Other useful cross-linkers, not considered to contain or generate a protected disulfide, include SATA, SPDP and 2 -iminothiolane. The use of such cross-linkers is well understood in the art. Flexible linkers may also be used.

[0087] U. S. Patent 4,680,338, describes bifunctional linkers useful for producing conjugates of ligands with amine-containing polymers and / or proteins, especially for forming antibody conjugates with chelators, drugs, enzymes, detectable labels and the like. U. S. Patents 5,141,648 and 5,563,250 disclose cleavable conjugates containing a labile bond that is cleavable under a variety of mild conditions. This linker is particularly useful in that the agent of interest may be bonded directly to the linker, with cleavage resulting in release of the active agent. Particular uses include adding a free amino or free sulfhydryl group to a protein, such as an antibody, or a drug.

[0088] U. S. Patent 5,856,456 provides peptide linkers for use in connecting polypeptide constituents to make fusion proteins, e.g, single chain antibodies. The linker is up to about 50 amino acids in length, contains at least one occurrence of a charged amino acid (preferably arginine or lysine) followed by a proline, and is characterized by greater stability and reduced aggregation. U. S. Patent 5,880,270 discloses aminooxy-containing linkers useful in a variety of immunodiagnostic and separative techniques.C. Bispecific and Multispecific Antibodies

[0089] Antibodies may be bispecific or multispecific. “Bispecific antibodies” are antibodies that have binding specificities for at least two different epitopes. Exemplary bi specific antibodies may bind to two different epitopes of a single antigen. Other such antibodies may combine a first antigen binding site with a binding site for a second antigen. Alternatively, an antigen-specific arm may be combined with an arm that binds to a triggering molecule on a leukocyte, such as a T-cell receptor molecule (e.g., CD3), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and Fc gamma RIII (CD16), so as to focus and localize cellular defense mechanisms to the diseased cell. Bispecific antibodies may also be used to localize cytotoxic agents to infected cells. These antibodies possess an antigenbinding arm and an arm that binds the cytotoxic agent e.g., saporin, anti-interferon-a, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g, F(ab')2 bispecific antibodies).244903-1524-0106, v. 1

[0090] Methods for making bispecific antibodies are known in the art. Traditional production of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains⁻¹ave different specificities. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low.

[0091] According to a different approach, antibody variable regions with the desired binding specificities (antibody -antigen combining sites) are fused to immunoglobulin constant domain sequences. Preferably, the fusion is with an Ig heavy chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light chain bonding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host cell. This provides for greater flexibility in adjusting the mutual proportions of the three polypeptide fragments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yield of the desired bispecific antibody. It is, however, possible to insert the coding sequences for two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios⁻¹ave no significant effect on the yield of the desired chain combination.

[0092] The bispecific antibodies may be composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chainlight chain pair (providing a second binding specificity) in the other arm. This asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94 / 04690. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0093] According to another approach described in U. S. Pat. No. 5,731,168, the interface between a pair of antibody molecules can be engineered to maximize the percentage254903-1524-0106, v. 1of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as⁻¹omodimers.

[0094] Bispecific antibodies include cross-linked or “heteroconjugate” antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies⁻¹ave, for example, been proposed to target immune system cells to unwanted cells (U. S. Pat. No. 4,676,980). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U. S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[0095] Techniques for generating bispecific antibodies from antibody fragments⁻¹ave also been described in the literature. For example, bi specific antibodies can be prepared using chemical linkage. Brennan et al.. Science, 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent, sodium arsenite, to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethyl amine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[0096] Techniques exist that facilitate the direct recovery of Fab'-SH fragments from E. coli, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describe the production of a humanized bispecific antibody F(ab')2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.264903-1524-0106, v. 1

[0097] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described (Merchant et al., Nat. Biotechnol. 16, 677-681 (1998)). For example, bispecific antibodies⁻¹ave been produced using leucine zippers (Kostelny et al., J, Immunol., 148(5): 1547-1553, 1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab’ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger etal., Proc. Natl. Acad. Sei. USA, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a VH connected to a VL by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers⁻¹as also been reported. See Gruber et al., J. Immunol., 152:5368 (1994).

[0098] A bispecific or multispecific antibody may be formed as a DOCK-AND- LOCK™ (DNL™) complex (see, e.g., U. S. Pat. Nos. 7,521,056; 7,527,787; 7,534,866; 7,550,143 and 7,666,400). Generally, the technique takes advantage of the specific and high-affinity binding interactions that occur between a dimerization and docking domain (DDD) sequence of the regulatory (R) subunits of cAMP-dependent protein kinase (PKA) and an anchor domain (AD) sequence derived from any of a variety of AK AP proteins (Baillie et al., FEBS Letters. 2005; 579: 3264; Wong and Scott, Nat. Rev. Mol. Cell Biol. 2004; 5: 959). The DDD and AD peptides may be attached to any protein, peptide or other molecule. Because the DDD sequences spontaneously dimerize and bind to the AD sequence, the technique allows the formation of complexes between any selected molecules that may be attached to DDD or AD sequences.

[0099] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared (Tutt etal., J. Immunol. 147: 60, 1991; Xu etal.. Science, 358(6359):85-90, 2017). The antibodies may also involve sequences or moieties that permit dimerization or multimerization of the receptors. Such sequences include those derived from IgA, which pennit formation of multimers in conjunction with the J-chain, Another multimerization domain is the Gal4 dimerization domain.274903-1524-0106, v. 1

[0100] A multivalent antibody may be internalized (and / or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibody binds. The antibodies of the present disclosure can be multivalent antibodies with three or more antigen binding sites (e.g., tetraval ent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. The preferred dimerization domain comprises (or consists of) an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. Multivalent antibodies may comprise (or consist of) three to about eight, for example four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable regions. For instance, the polypeptide chain(s) may comprise VD1-(X1).sub.n-VD2-(X2)n-Fc, wherein VD1 is a first variable region, VD2 is a second variable region, Fc is one polypeptide chain of an Fc region, XI and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CHl-flexible linker- VH-CHl-Fc region chain; or VH-CHl-VH-CHl-Fc region chain. The multivalent antibody herein may further comprise at least two (and preferably four) light chain variable region polypeptides. The multivalent antibody herein may, for instance, comprise from about two to about eight light chain variable region polypeptides. The light chain variable region polypeptides contemplated here comprise a light chain variable region and, optionally, further comprise a CL domain.

[0101] Charge modifications are particularly useful in the context of a multispecific antibody, where amino acid substitutions in Fab molecules result in reducing the mispairing of light chains with non-matching heavy chains (Bence-Jones-type side products), which can occur in the production of Fab-based bi- / multispecific antigen binding molecules with a VH / VL exchange in one (or more, in case of molecules comprising more than two antigenbinding Fab molecules) of their binding arms (see also PCT publication no. WO 2015 / 150447, particularly the examples therein, incorporated herein by reference in its entirety).D Antibody Conjugates

[0102] Antibodies of the present disclosure may be linked to at least one agent to form an antibody conjugate. The conjugate can be, for example, an antibody conjugated to another proteinaceous, carbohydrate, lipid, or mixed moiety molecule(s). Such antibody conjugates284903-1524-0106, v. 1include, but are not limited to, modifications that include linking the antibody to one or more polymers. For example, an antibody may be linked to one or more water-soluble polymers. Linkage to a water-soluble polymer reduces the likelihood that the antibody will precipitate in an aqueous environment, such as a physiological environment. One skilled in the art can select a suitable water-soluble polymer based on considerations including, but not limited to, whether the polymer / antibody conjugate will be used in the treatment of a patient and, if so, the pharmacological profile of the antibody (e.g., half-life, dosage, activity, antigenicity, and / or other factors).

[0103] In order to increase the efficacy of antibody molecules as diagnostic or therapeutic agents, it is conventional to link or covalently bind or complex at least one desired molecule or moiety. Such a molecule or moiety may be, but is not limited to, at least one effector or reporter molecule. Effector molecules comprise molecules⁻¹aving a desired activity, e.g., cytotoxic activity. Non-limiting examples of effector molecules which have been attached to antibodies include toxins, anti-tumor agents, therapeutic enzymes, radionuclides, antiviral agents, chelating agents, cytokines, growth factors, and oligo- or polynucleotides. By contrast, a reporter molecule is defined as any moiety which may be detected using an assay. Non¬ limiting examples of reporter molecules which have been conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, photoaffinity molecules, colored particles or ligands, an enzyme e.g., that catalyzes a colorimetric or fluorometric reaction), a substrate, a solid matrix, such as biotin. An antibody may comprise one, two, or more of any of these labels.

[0104] Antibody conjugates are also used as diagnostic agents. Antibody diagnostics generally fall within two classes, those for use in in vitro diagnostics, such as in a variety of immunoassays, and those for use in vivo diagnostic protocols, generally known as “antibody-directed imaging.” Many appropriate imaging agents are known in the art, as are methods for their attachment to antibodies (see, for e.g., U. S. Patents 5,021,236, 4,938,948, and 4,472,509). The imaging moieties used can be paramagnetic ions, radioactive isotopes, fluorochromes, NMR-detectable substances, and X-ray imaging agents.

[0105] The paramagnetic ions contemplated for use as conjugates include chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and / or erbium (III), with gadolinium being particularly preferred. Ions useful in294903-1524-0106, v. 1other contexts, such as X-ray imaging, include but are not limited to lanthanum (III), gold (III), lead (II), and bismuth (III).

[0106] The radioactive isotopes contemplated for use as conjugated include astatine211,14carbon,51chromium,36chlorine,57cobalt,58cobalt, copper67,152Eu, gallium67,3hydrogen, iodine123, iodine123, iodine131, indium111,39iron,32phosphorus, rhenium186, rhenium188,75selenium,35sulphur, technicium99™ and / or yttrium90.!25I is often being preferred. Technician!99™ and / or indium111are also often preferred due to their low energy and suitability for long range detection. Radioactively labeled monoclonal antibodies of the present disclosure may be produced according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium and / or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase. Monoclonal antibodies according to the disclosure may be labeled with technetium99™ by ligand exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column. Alternatively, direct labeling techniques may be used, e.g, by incubating pertechnate, a reducing agent such as SNCI2, a buffer solution such as sodium-potassium phthalate solution, and the antibody. Intermediary functional groups which are often used to bind radioisotopes which exist as metallic ions to antibody are diethylenetriaminepentaacetic acid (DTP A) or ethylene di aminetetracetic acid (EDTA).

[0107] The fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, tetramethylrhodamine, and / or Texas Red.

[0108] Additional types of antibodies contemplated in the present disclosure are those intended primarily for use in vitro, where the antibody is linked to a secondary binding ligand and / or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase. Preferred secondary binding ligands are biotin and avidin and streptavidin compounds.304903-1524-0106, v. 1

[0109] Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Some attachment methods involve the use of a metal chelate complex employing, for example, an organic chelating agent such a diethylenetriaminepentaacetic acid anhydride (DTPA); ethylenetriaminetetraacetic acid; N-chloro-p-toluenesulfonamide; and / or tetrachloro-3a-6a-diphenylglycouril-3 attached to the antibody (U. S. Patents 4,472,509 and 4,938,948). Monoclonal antibodies may also be reacted with an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate. In U. S. Patent 4,938,948, imaging of breast tumors is achieved using monoclonal antibodies and the detectable imaging moieties are bound to the antibody using linkers such as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hy droxy pheny l)propi on ate.

[0110] Another known method of site-specific attachment of molecules to antibodies comprises the reaction of antibodies with hapten-based affinity labels. Essentially, hapten¬ based affinity labels react with amino acids in the antigen binding site, thereby destroying this site and blocking specific antigen reaction. However, this may not be advantageous since it results in loss of antigen binding by the antibody conjugate.

[0111] Molecules containing azido groups may also be used to form covalent bonds to proteins through reactive nitrene intermediates that are generated by low intensity ultraviolet light. In particular, 2- and 8-azido analogues of purine nucleotides⁻¹ave been used as site- directed photoprobes to identify nucleotide binding proteins in crude cell extracts. The 2- and 8-azido nucleotides⁻¹ave also been used to map nucleotide binding domains of purified proteins and may be used as antibody binding agents.

[0112] Derivatization of immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of an immunoglobulin, using reaction conditions that do not alter the antibody combining site are also contemplated. Antibody conjugates produced according to this methodology are disclosed to exhibit improved longevity, specificity and sensitivity (U. S. Patent 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region have also been disclosed in the literature. This approach has been reported to produce diagnostically and therapeutically promising antibodies which are currently in clinical evaluation.314903-1524-0106, v. 1E. Antibody Drug Conjugates

[0113] Antibody drug conjugates, or ADCs, are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with disease. ADCs are complex molecules composed of an antibody (a whole mAb or an antibody fragment, such as a scFv) linked, via a stable chemical linker with labile bonds, to a biological active cytotoxic / anti-viral payload or drug. Antibody drug conjugates are examples of bioconjugates and immunoconjugates.

[0114] By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional systemic approaches, antibody-drug conjugates target and attack the diseased cell so that healthy cells are less severely affected.

[0115] In the development of ADC-based anti -turn or therapies, an anticancer drug (e.g, a cell toxin or cytotoxin) is coupled to an antibody that specifically targets a certain cell marker (e.g., a protein that, ideally, is only to be found in or on diseased cells). Antibodies track these proteins down in the body and attach themselves to the surface of the diseased cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the targeted cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cell or impairs cellular replication. Due to this targeting, ideally the drug has lower side effects and gives a wider therapeutic window than other agents.

[0116] Linkers are based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (noncleavable) and control the distribution and delivery of the cytotoxic agent to the target cell. Cleavable and non-cleavable types of linkers⁻¹ave been proven to be safe in preclinical and clinical trials. Brentuximab vedotin includes an enzyme¬ sensitive cleavable linker that delivers the potent and highly toxic antimicrotubule agent Monomethyl auristatinE or MMAE, a synthetic antineoplastic agent, to human specific CD30-positive malignant cells. Because of its⁻¹igh toxicity MMAE, which inhibits cell division by blocking the polymerization of tubulin, cannot be used as a single-agent chemotherapeutic drug. However, the combination of MMAE linked to an anti-CD30 monoclonal antibody (cAClO, a cell membrane protein of the tumor necrosis factor or TNF receptor) proved to be stable in extracellular fluid, cleavable by cathepsin and safe for therapy. Trastuzumab324903-1524-0106, v. 1emtansine, the other approved ADC, is a combination of the microtubule-formation inhibitor mertansine (DM-1), a derivative of the Maytansine, and antibody trastuzumab (Herceptin Genentech / Roche) attached by a stable, non-cleavable linker.

[0117] The availability of better and more stable linkers⁻¹as changed the function of the chemical bond. The type of linker, cleavable or noncleavable, lends specific properties to the cytotoxic (e.g., anti -cancer) drug. For example, a non-cleavable linker keeps the drug within the cell. As a result, the entire antibody, linker, and cytotoxic agent enter the targeted cell where the antibody is degraded to the level of amino acids. The resulting complex - amino acid, linker and cytotoxic agent - now becomes the active drug. In contrast, cleavable linkers are catalyzed by enzymes in the host cell, thereby releasing the cytotoxic agent.

[0118] Another type of cleavable linker adds an extra molecule between the cytotoxic drug and the cleavage site. This linker technology allows researchers to create ADCs with more flexibility without worrying about changing cleavage kinetics. Researchers are also developing a new method of peptide cleavage based on Edman degradation. Future direction in the development of ADCs also include the development of site-specific conjugation (TDCs) to further improve stability and therapeutic index and a-emitting immunoconjugates and antibody-conjugated nanoparticles.

[0119] An antibody may be covalently linked (e.g., a genetic fusion protein) to an ADP-ribosyl cyclase protein. The ADP-ribosyl cyclase protein may be a mammalian ADP-ribosyl cyclase protein. For example, the ADP-ribosyl cyclase protein may include a human ADP-ribosyl cyclase protein, a murine ADP-ribosyl cyclase protein, a porcine ADP-ribosyl cyclase protein, or a bovine ADP-ribosyl cyclase protein. Preferably, the ADP-ribosyl cyclase protein is⁻¹uman, mouse, or bovine CD38 or BST1. Preferably, the CD38 and BST1 protein (UniProtKB: Q 10588) are human. More preferably, the ADP-ribosyl cyclase protein is⁻¹uman CDS 8, e.g.:MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTT KRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLG TQTVPCNKILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINY QSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGS j^ VHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFL QCVKNPEDSSCTSEI (SEQ ID NO: 10) (Glutamate 226 is boxed)

[0120] The ADP-ribosyl cyclase protein may comprise a catalytic subunit or extracellular domain of CD38 (e.g., V45-I300), e.g.:334903-1524-0106, v. 1RWRQQWSGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCN ITEEDYQPLMKLGI QTVPCNKILL WSR1KDL AHQF TQ VQRDMFTLEDTLLGYLADDL TWCGEFNTSKINYQSCPDWRKDCSNNPVSVFWKTVSRRFAEAACDVVHVMLNGSR SKIFDKNSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNI QFSCKNIYRPDKFLQCVKNPEDSSCTSEI (SEQ ID NO: 11)orRWRQQWSGPGTTKRFPETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCD ITEEDYQPLMKLGTQTVPCNK ILLWSRIKDL Al IQFTQVQRDMFT1 J3DTLLGYL A DDI, WCGEFATSKINYQSCPDWRKDCSNNPVSATWKTVSRRFAEAACDVVHVMLDGSR SKIFDKDSTFGSVEVHNLQPEKVQTLEAWVIHGGREDSRDLCQDPTIKELESIISKRNI QFSCKNIYRPDKFLQCVKNPEDSSCTSEI (SEQ ID NO: 12).

[0121] Alternatively, the ADP-ribosyl cyclase protein may include a plant ADP-ribosyl cyclase protein (e.g., CD38, BST1).

[0122] ADC as provided herein may include a peptide linker moiety disposed between the antibody and the ADP-ribosyl cyclase protein. More preferably, the peptide linker may comprise one or more of a GGS peptide, a (GGGS)npeptide (SEQ ID NOs: 13-17), or a (GGGGS)n peptide (SEQ ID NOs: 18-22), where n is an integer from 1 to 5. For example, the peptide linker may be GGGGS (SEQ ID NO: 18).

[0123] A payload may be conjugated to the 2'-modified araNAD^ analogue or the 2'-modified araNMN analogue. Preferably, the payload may be a chemotoxic agent comprising auri statin, calicheamicin, maytansine, duocarmycin, a camptothecin analogue such as SN38 or DX-8951, or a benzodiazepine such as PBD, talirine, tesirine, or indolinobenzodiazepines. Preferably, auristatin is monomethyl auristatin F.

[0124] Other agents that may be used as a payload include, but is not limited to, therapeutic agents of use in combination with the conjugates described herein also include, for example, chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxins, taxanes, antimetabolites, tyrosine kinase inhibitors, alkylating agents, antibiotics, Cox-2 inhibitors, antimitotics, anti angiogenic and proapoptotic agents, particularly doxorubicin, methotrexate, taxol, other camptothecins, and others from these and other classes of anticancer agents, and the like. Other cancer chemotherapeutic drugs include nitrogen mustards, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, pyrimidine analogs, purine analogs, platinum coordination complexes, hormones, and the like. Suitable chemotherapeutic agents are described in Remington’s Pharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995), and in Goodman and Gilman's The Pharmacological Basis of Therapetuics, 7th Ed. (MacMillan344903-1524-0106, v. 1Publishing Co. 1985), as well as revised editions of these publications. Other suitable chemotherapeutic agents, such as experimental drugs, are known to those of skill in the art.

[0125] Other exemplary active agents include, but are not limited to, 5-fluorouracil, afatinib, aplidin, azaribine, anastrozole, anthracy clines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxy camptothecin, carmustine, celebrex, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, erlotinib, estraniustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fmgolimod, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, famesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, L-asparaginase, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU 11248, sunitinib, tamoxifen, temazolomide (an aqueous form of DTIC), transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, and ZD1839. Such agents may be part of the conjugates described herein or may alternatively be administered in combination with the described conjugates, either prior to, simultaneously with or after the conjugate.

[0126] The payload and the 2'-modified araNAD+analogue (e.g., 6-azido-2'-Cl-araNAD+) may include a functional group or moiety that is capable of undergoing a click chemistry reaction. The click chemistry approach was originally conceived as a method to rapidly generate complex substances by joining small subunits together in a modular fashion. (See, e.g., Evans, R A, 2007, AustJChem 60(6 ): 384-95.) Multiple variations of click chemistry reaction are known in the art, such as the Huisgen 1,3-dipolar cycloaddition copper catalyzed reaction (Tomoe et al., 2002, J Org Chem 67:3057-64). Other alternative reaction mechanisms include cycloaddition reactions such as the Diels-Alder, nucleophilic substitution reactions354903-1524-0106, v. 1(especially to small, strained rings like epoxy and aziridine compounds), carbonyl chemistry' formation of urea compounds and reactions involving carbon-carbon double bonds, such as alkynes in thiol-yne reactions.

[0127] The azide alkyne Huisgen cycloaddition reaction uses a copper catalyst in the presence of a reducing agent to catalyze the reaction of a terminal alkyne group attached to a first molecule. In the presence of a second molecule comprising, for example, an azide moiety, the azide reacts with the activated alkyne to form a 1,4-disubstituted 1,2, 3 -tri azole. Advantageously the copper catalyzed reaction occurs at room temperature and is sufficiently specific that purification of the reaction product is often not required. (Tornoe et al., 2002, J Org Chem 67:3057.) Advantageously, the azide and alkyne functional groups are largely inert towards biomolecules in aqueous medium, thus permitting the reaction to occur in complex solutions. The resultant triazole is chemically stable and may not be subject to enzymatic cleavage, making the click chemistry product highly stable in biological systems. And although the copper catalyst is toxic to living cells, the copper-based click chemistry reaction may be used in vitro for immunoconjugate formation.

[0128] A copper-free click reaction also has been proposed for covalent modification of biomolecules. (See, e.g., Agard et al., J. Am. Chem. Soc. 2004, 126, 46, 15046-15047) In this system, the copper-free reaction uses ring strain in place of the copper catalyst to promote a [3+2] azide-alkyne cycloaddition reaction. For example, cyclooctyne is an 8-carbon ring structure comprising an internal alkyne bond. The closed ring structure induces a substantial bond angle deformation of the acetylene, which is⁻¹ighly reactive with azide groups to form a triazole. Thus, cyclooctyne derivatives may be used for copper-free click reactions.

[0129] Another type of copper-free click reaction (Ning et al., Angew Chem Int Ed Engl. 2010 Apr. 12; 49(17): 3065-3068.), is based upon strain-promoted alkyne-nitrone cycloaddition. To address the slow rate of the original cyclooctyne reaction, electron¬ withdrawing groups are attached adjacent to the triple bond. Examples of such substituted cyclooctynes include difluorinated cyclooctynes, 4-dibenzocyclooctynol and azacyclooctyne. An alternative copper-free reaction involved strain-promoted alkyne-nitrone cycloaddition to give N-alkylated isoxazolines. The reaction was reported to have exceptionally fast reaction kinetics and was used in a one-pot three-step protocol for site-specific modification of peptides and proteins. Nitrones were prepared by the condensation of appropriate aldehydes with N-m ethylhydroxyl amine and the cycloaddition reaction took place in a mixture of acetonitrile and364903-1524-0106, v. 1water. These and other known click chemistry reactions may be used to attach carrier moieties to antibodies in vitro.

[0130] In the click chemistry reaction, the reactive group may comprise an alkyne that can undergo a 1,3 -cycloaddition reaction with an azide. Such suitable reactive groups include, but are not limited to, strained alkynes, e.g., those suitable for strain-promoted alkyne-azide cycloadditions (SPAAC), cycloalkynes, e.g., cyclooctynes, benzannulated alkynes, and alkynes capable of undergoing 1,3 cycloaddition reactions with azides in the absence of copper catalysts. Suitable alkynes also include, but are not limited to, substituted alkynes, e.g., fluorinated alkynes, aza-cycloalkynes, BCN, and derivatives thereof. Linker-agent comprising such reactive groups are useful for conjugating antibodies that have been functionalized with azido groups. Such functionalized antibodies include antibodies functionalized with azido¬ polyethylene glycol groups.

[0131] The active agent may be a diagnostic agent useful for diagnosis of a certain condition or disease. Examples of detectable agents include various enzymes, prosthetic groups, fluorescent materials (e.g., fluorescein, rhodamine, Cy5), luminescent materials, bioluminescent materials, green fluorescence protein (GFP), a variant of GFP, a resonance energy transfer (RET) donor molecule, a RET acceptor molecule, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include125I,131I,111In and " Tc.F. Production and Purification of Antibodies

[0132] The methods for generating monoclonal antibodies generally begin along the same lines as those for preparing polyclonal antibodies. The first step for both of these methods is immunization of an appropriate host. As is well known in the art, a given composition for immunization may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a374903-1524-0106, v. 1earner. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA), Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobencoyl-N-hydroxysuccinimide ester, carbodiimyde and bis-biazotized benzidine. As also is well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants in animals include complete Freund’s adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund’s adjuvants and aluminum hydroxide adjuvant and in humans include alum, CpG, MFP59, and combinations of immunostimulatory molecules (“Adjuvant Systems”, such as AS01 or AS03). Additional experimental forms of inoculation to induce antigen-specific B cells are possible, including nanoparticle vaccines, or gene-encoded antigens delivered as DNA or RNA genes in a physical delivery system (such as lipid nanoparticle or on a gold biolistic bead), and delivered with needle, gene gun, or transcutaneous electroporation device. The antigen gene also can be carried as encoded by a replication competent or defective viral vector such as adenovirus, adeno-associated virus, poxvirus, herpesvirus, or alphavirus replicon, or alternatively a viruslike particle.

[0133] Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20: 1 to about 1:1, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. In some cases, transformation of human B cells with Epstein Barr virus (EBV) as an initial step increases the size of the B cells, enhancing fusion with the relatively large-sized myeloma cells. Transformation efficiency by EBV is enhanced by using CpG and a Chk2 inhibitor drug in the transforming medium. / Alternatively, human B cells can be activated by co-culture with transfected cell lines expressing CD40 Ligand (CD 154) in medium containing additional soluble factors, such as IL-21 and human B cell Activating Factor (BAFF), a Type II member of the TNF superfamily. Fusion methods using Sendai virus or polyethylene glycol (PEG) are also known. The use of electrically induced fusion methods is also appropriate. Fusion procedures usually produce viable hybrids at low frequencies, about 1 x 10“6to 1 x 10‘8, but with optimized procedures one can achieve fusion efficiencies close to I in 200. However, relatively low efficiency of fusion does not pose a problem, as the viable, fused hybrids are384903-1524-0106, v. 1differentiated from the parental, infused cells (particularly the infused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture medium. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the medium is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the medium is supplemented with hypoxanthine. Ouabain is added if the B cell source is an EB V -transformed human B cell line, in order to eliminate EBV-transformed lines that have not fused to the myeloma.

[0134] The preferred selection medium is HAT or HAT with ouabain. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells. When the source of B cells used for fusion is a line of EBV-transformed B cells, as⁻¹ere, ouabain may also be used for drug selection of hybrids as EBV-transformed B cells are susceptible to drug killing, whereas the myeloma partner used is chosen to be ouabain resistant.

[0135] Culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by singleclone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays dot immunobinding assays, and the like. The selected hybridomas are then serially diluted or single-cell sorted by flow cytometric sorting and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide monoclonal antibodies. The cell lines may be exploited for monoclonal antibody production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into an animal (e.g, a mouse). Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. When human hybridomas are used in this394903-1524-0106, v. 1way, it is optimal to inject immunocompromised mice, such as SCID mice, to prevent tumor rejection. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide monoclonal antibodies in high concentration. The individual cell lines could also be cultured in vitro, where the monoclonal antibodies are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. Alternatively, human hybridoma cells lines can be used in vitro to produce immunoglobulins in cell supernatant. The cell lines can be adapted for growth in serum-free medium to optimize the ability to recover human monoclonal immunoglobulins of high purity.

[0136] Hybridomas may be cultured, then cells lysed, and total RNA extracted. Random hexamers may be used with RT to generate cDNA copies of RNA, and then PCR performed using a multiplex mixture of PCR primers expected to amplify all human variable gene sequences. PCR product can be cloned into pGEM-T Easy vector, then sequenced by automated DNA sequencing using standard vector primers. Assay of binding and neutralization may be performed using antibodies collected from hybridoma supernatants and purified by FPLC, using Protein G columns.

[0137] Recombinant full-length IgG antibodies can be generated by subcloning heavy and light chain Fv DNAs from the cloning vector into an IgG plasmid vector, transfected into 293 (e.g., Freestyle) cells or CHO cells, and antibodies can be collected and purified from the 293 or CHO cel 1 supernatant. Other appropriate host cells systems include bacteria, such as E. coli, insect cells (S2, Sf9, Sf29, High Five), plant cells e.g., tobacco, with or without engineering for human-like glycans), algae, or in a variety of non-human transgenic contexts, such as mice, rats, goats or cows.

[0138] Expression of nucleic acids encoding antibodies, both for the purpose of subsequent antibody purification, and for immunization of a host, is also contemplated. Antibody coding sequences can be RNA, such as native RNA or modified RNA. Modified RNA contemplates certain chemical modifications that confer increased stability and low immunogenicity to mRNAs, thereby facilitating expression of therapeutically important proteins. For instance, Nl-methyl-pseudouridine (Nlm'P) outperforms several other nucleoside modifications and their combinations in terms of translation capacity. In addition to turning off the immune / eIF2a phosphorylation-dependent inhibition of translation, incorporated Nlm'P nucleotides dramatically alter the dynamics of the translation process by404903-1524-0106, v. 1increasing ribosome pausing and density on the mRNA. Increased ribosome loading of modified mRNAs renders them more permissive for initiation by favoring either ribosome recycling on the same mRNA or de novo ribosome recruitment. Such modifications could be used to enhance antibody expression in vivo following inoculation with RNA. The RNA, whether native or modified, may be delivered as naked RNA or in a delivery vehicle, such as a lipid nanoparticle.

[0139] Alternatively, DNA encoding the antibody may be employed for the same purposes. The DNA is included in an expression cassette comprising a promoter active in the host cell for which it is designed. The expression cassette is advantageously included in a replicable vector, such as a conventional plasmid or minivector. Vectors include viral vectors, such as poxviruses, adenoviruses, herpesviruses, adeno-associated viruses, and lentiviruses are contemplated. Replicons encoding antibody genes such as alphavirus replicons based on VEE vims or Sindbis vims are also contemplated. Delivery of such vectors can be performed by needle through intramuscular, subcutaneous, or intradermal routes, or by transcutaneous electroporation when in vivo expression is desired.

[0140] Alternatively, a molecular cloning approach may be used to generate monoclonal antibodies. Single B cells labeled with the antigen of interest can be sorted physically using paramagnetic bead selection or flow cytometric sorting, then RNA can be isolated from the single cells and antibody genes amplified by RT-PCR. Alternatively, antigen¬ specific bulk sorted populations of cells can be segregated into microvesicles and the matched heavy and light chain variable genes recovered from single cells using physical linkage of heavy and light chain amplicons, or common barcoding of heavy and light chain genes from a vesicle. Matched heavy and light chain genes form single cells also can be obtained from populations of antigen specific B cells by treating cells with cell-penetrating nanoparticles bearing RT-PCR primers and barcodes for marking transcripts with one barcode per cell. The antibody variable genes also can be isolated by RNA extraction of a hybridoma line and the antibody genes obtained by RT-PCR and cloned into an immunoglobulin expression vector. Alternatively, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the cell lines and phagemids expressing appropriate antibodies are selected by panning using viral antigens. The advantages of this approach over conventional hybridoma techniques are that approximately 104times as many antibodies can be produced and screened414903-1524-0106, v. 1in a single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

[0141] Other U. S. patents, each incorporated herein by reference, that teach the production of antibodies useful in the present disclosure include U. S. Patent 5,565,332, which describes the production of chimeric antibodies using a combinatorial approach; U. S. Patent 4,816,567 which describes recombinant immunoglobulin preparations; and U. S. Patent 4,867,973 which describes antibody-therapeutic agent conjugates.

[0142] Monoclonal antibodies produced by any means may be purified, if desired, using filtration, centrifugation, and various chromatographic methods, such as FPLC or affinity chromatography. Fragments of the monoclonal antibodies of the disclosure can be obtained from the purified monoclonal antibodies by methods that include digestion with enzymes, such as pepsin or papain, and / or by cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present disclosure can be synthesized using an automated peptide synthesizer.

[0143] The antibodies of the present disclosure may be purified. The term “purified,” as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein is purified to any degree relative to its naturally obtainable state. A purified protein therefore also refers to a protein, free from the environment in which it may naturally occur. Where the term “substantially purified” is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more of the proteins in the composition.

[0144] Protein purification techniques are well known to those of skill in the art. These techniques involve, at one level, the crude fractionation of the cellular milieu to polypeptide and non-polypeptide fractions. Having separated the polypeptide from other proteins, the polypeptide of interest may be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity). Analytical methods particularly suited to the preparation of a pure peptide are ion-exchange chromatography, exclusion chromatography; polyacrylamide gel electrophoresis; isoelectric focusing. Other methods for protein purification include, precipitation with ammonium sulfate, PEG, antibodies and the like or by heat denaturation, followed by centrifugation; gel filtration,424903-1524-0106, v. 1reverse phase, hydroxylapatite and affinity chromatography; and combinations of such and other techniques.

[0145] In purifying an antibody of the present disclosure, it may be desirable to express the polypeptide in a prokaryotic or eukaryotic expression system and extract the protein using denaturing conditions. The polypeptide may be purified from other cellular components using an affinity column, which binds to a tagged portion of the polypeptide. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

[0146] Commonly, complete antibodies are fractionated utilizing agents ( / .e., protein A) that bind the Fc portion of the antibody. Alternatively, antigens may be used to simultaneously purify and select appropriate antibodies. Such methods often utilize the selection agent bound to a support, such as a column, filter or bead. The antibodies are bound to a support, contaminants removed (e.g, washed away), and the antibodies released by applying conditions (salt, heat, etc.).

[0147] Various methods for quantifying the degree of purification of the protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the amount of polypeptides within a fraction by SDS / PAGE analysis. Another method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity. The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.

[0148] It is known that the migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS / PAGE. It will therefore be appreciated that under differing electrophoresis conditions, the apparent molecular weights of purified or partially purified expression products may vary.434903-1524-0106, v. 1G. Modification of Antibodies

[0149] The sequences of antibodies may be modified for a variety of reasons, such as improved expression, improved cross-reactivity, or diminished off-target binding. Modified antibodies may be made by any technique known to those of skill in the art, including expression through standard molecular biological techniques, or the chemical synthesis of polypeptides.

[0150] For example, one may wish to make modifications, such as introducing conservative changes into an antibody molecule. In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

[0151] The substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. As detailed in U. S. Patent 4,554, 101, the following hydrophilicity values⁻¹ave been assigned to amino acid residues: basic amino acids: arginine (+3.0), lysine (+3.0), and histidine (-0.5); acidic amino acids: aspartate (+3.0 ± I), glutamate (+3.0 ± 1), asparagine (+0.2), and glutamine (+0.2); hydrophilic, nonionic amino acids: serine (+0.3), asparagine (+0.2), glutamine (+0.2), and threonine (-0.4), sulfur containing amino acids: cysteine (-1.0) and methionine (-1.3); hydrophobic, nonaromatic amino acids: valine (-1.5), leucine (-1.8), isoleucine (-1.8), proline (-0.5 ± 1), alanine (-0.5), and glycine (0); hydrophobic, aromatic amino acids: tryptophan (-3.4), phenylalanine (-2.5), and tyrosine (-2.3).

[0152] An amino acid can be substituted for another having a similar hydrophilicity and produce a biologically or immunologically modified protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.444903-1524-0106, v. 1

[0153] Amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take into consideration the various foregoing characteristics are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

[0154] The present disclosure also contemplates isotype modification. By modifying the Fc region to have a different isotype, different functionalities can be achieved. For example, changing to IgGi can increase antibody dependent cell cytotoxicity, switching to class A can improve tissue distribution, and switching to class M can improve valency.

[0155] One can design an Fc region of an antibody with altered effector function, e.g., by modifying Clq binding and / or FcyR binding and thereby changing CDC activity and / or ADCC activity. “Effector functions” are responsible for activating or diminishing a biological activity (e.g, in a subject). Examples of effector functions include, but are not limited to: Clq binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g, B cell receptor; BCR), etc. Such effector functions may require the Fc region to be combined with a binding domain (e.g, an antibody variable domain) and can be assessed using various assays (e.g, Fc binding assays, ADCC assays, CDC assays, etc.

[0156] For example, one can generate a variant Fc region of an antibody with improved Clq binding and improved FcyRIII binding (e.g, having both improved ADCC activity and improved CDC activity). Alternatively, if it is desired that effector function be reduced or ablated, a variant Fc region can be engineered with reduced CDC activity and / or reduced ADCC activity. Only one of these activities may be increased, and, optionally, also the other activity reduced (e.g., to generate an Fc region variant with improved ADCC activity, but reduced CDC activity and vice versa.

[0157] An isolated monoclonal antibody, or antigen binding fragment thereof, may contain a substantially homogeneous glycan without sialic acid, galactose, or fucose. The aforementioned substantially homogeneous glycan may be covalently attached to the heavy chain constant region.454903-1524-0106, v. 1

[0158] A monoclonal antibody may have a novel Fc glycosylation pattern. Glycosylation of an Fc region is typically either N-linked or O-linked, N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain peptide sequences are asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline. Thus, the presence of either of these peptide sequences in a polypeptide creates a potential glycosylation site.

[0159] The glycosylation pattern may be altered, for example, by deleting one or more glycosylation site(s) found in the polypeptide, and / or adding one or more glycosylation site(s) that are not present in the polypeptide. Addition of glycosylation sites to the Fc region of an antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). An exemplary glycosylation variant has an amino acid substitution of residue Asn 297 of the heavy chain. The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original polypeptide (for O-linked glycosylation sites). Additionally, a change of Asn 297 to Ala can remove one of the glycosylation sites.

[0160] The isolated monoclonal antibody, or antigen binding fragment thereof, may be present in a substantially homogenous composition represented by the GNGN or G1 / G2 glycoform, which exhibits increased binding affinity for Fc gamma RI and Fc gamma RIII compared to the same antibody without the substantially homogeneous GNGN glycoform and with GO, GIF, G2F, GNF, GNGNF or GNGNFX containing glycoforms. Fc glycosylation plays a significant role in anti-viral and anti-cancer properties of therapeutic mAbs. Elimination of core fucose dramatically improves the ADCC activity of mAbs mediated by natural killer (NK) cells but appears to have the opposite effect on the ADCC activity of polymorphonuclear cells (PMNs).

[0161] The isolated monoclonal antibody, or antigen binding fragment thereof, may be expressed in cells that express beta (l,4)-N-acetylglucosaminyltransf erase III (GnT III), such that GnT III adds GlcNAc to the antibody. Methods for producing antibodies in such a fashion are provided in WO / 9954342 and WO / 03011878. Cell lines can be altered to enhance or reduce464903-1524-0106, v. 1or eliminate certain post-translational modifications, such as glycosylation, using genome editing technology such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). For example, CRISPR technology can be used to eliminate genes encoding glycosylating enzymes in 293 or CHO cells used to express monoclonal antibodies.

[0162] It is possible to engineer the antibody variable gene sequences obtained from human B cells to enhance their manufacturability and safety. Potential protein sequence liabilities can be identified by searching for sequence motifs associated with sites containing:1 ) Unpaired Cys residues,2) N-linked glycosylation,3) Asn deamidation,4) Asp isomerization,5) SYE truncation,6) Met oxidation,7) Trp oxidation,8) N-terminal glutamate,9) Integrin binding,10 ) CD 11 c / CD 18 binding, or11) FragmentationSuch motifs can be eliminated by altering the synthetic gene comprising the cDNA encoding the antibodies.

[0163] Antibodies can be engineered to enhance solubility. For example, some hydrophilic residues such as aspartic acid, glutamic acid, and serine contribute significantly more favorably to protein solubility than other hydrophilic residues, such as asparagine, glutamine, threonine, lysine, and arginine.

[0164] B cell repertoire deep sequencing of human B cells from blood donors⁻¹as been performed on a wide scale. Sequence information about a significant portion of the human antibody repertoire facilitates statistical assessment of antibody sequence features common in healthy humans. With knowledge about the antibody sequence features in a human recombined antibody variable gene reference database, the position specific degree of “Human Likeness” (HL) of an antibody sequence can be estimated. HL has been shown to be useful for the development of antibodies in clinical use, like therapeutic antibodies or antibodies as vaccines. The goal is to increase the human likeness of antibodies to reduce potential adverse effects and474903-1524-0106, v. 1anti-antibody immune responses that will lead to significantly decreased efficacy of the antibody drug or can induce serious⁻¹ealth implications. One can assess antibody characteristics of the combined antibody repertoire of three healthy human blood donors of about 400 million sequences in total and created a novel “relative Human Likeness” (rHL) score that focuses on the hypervariable region of the antibody. The rHL score allows one to easily distinguish between human (positive score) and non-human sequences (negative score). Antibodies can be engineered to eliminate residues that are not common in human repertoires.H. Characterization of Anti bodies

[0165] Antibodies according to the present disclosure may be defined, in the first instance, by their binding specificity. Those of skill in the art, by assessing the binding specificity / affinity of a given antibody using techniques well known to those of skill in the art, can determine whether such antibodies fall within the scope of the instant claims. For example, the epitope to which a given antibody binds may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) amino acids located within the antigen molecule (i.e., a linear epitope in a domain). Alternatively, the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) located within the antigen molecule (e.g., a conformational epitope)

[0166] Various techniques known to persons of ordinary skill in the art can be used to determine whether an antibody “interacts with one or more amino acids” within a polypeptide or protein. Exemplary techniques include, for example, routine cross-blocking assays, such as that described in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, N. Y.). Cross-blocking can be measured in various binding assays such as ELISA, biolayer interferometry, or surface plasmon resonance. Other methods include alanine scanning mutational analysis, peptide blot analysis (Reineke (2004) Methods Mol. Biol. 248: 443-63), peptide cleavage analysis, high-resolution electron microscopy techniques using single particle reconstruction, cryoEM, or tomography, crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer (2000) Prot. Sci. 9: 487-496). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is⁻¹ydrogen / deuterium exchange detected by mass spectrometry. In general terms, the hydrogen / deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein / antibody484903-1524-0106, v. 1complex is transferred to water and exchangeable protons within amino acids that are protected by the antibody complex undergo deuteri um-to-hydrogen back-exchange at a slower rate than exchangeable protons within amino acids that are not part of the interface. As a result, amino acids that form part of the protein / antibody interface may retain deuterium and therefore exhibit relatively higher mass compared to amino acids not included in the interface. After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium-labeled residues which correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267: 252-259; Engen and Smith (2001) Anal. Chem. 73: 256A-265A,

[0167] The term “epitope” refers to a site on an antigen to which B and / or T cells respond. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.

[0168] Modification-Assisted Profiling (MAP), also known as Antigen Structure-based Antibody Profiling (ASAP) is a method that categorizes large numbers of monoclonal antibodies directed against the same antigen according to the similarities of the binding profile of each antibody to chemically or enzymatically modified antigen surfaces (see US 2004 / 0101920, herein specifically incorporated by reference in its entirety). Each category' may reflect a unique epitope either distinctly different from or partially overlapping with epitope represented by another category. This technology allows rapid filtering of genetically identical antibodies, such that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP may facilitate identification of rare hybridoma clones that produce monoclonal antibodies⁻¹aving the desired characteristics. MAP may be used to sort the antibodies of the disclosure into groups of antibodies binding different epitopes.

[0169] The present disclosure includes antibodies that may bind to the same epitope, or a portion of the same epitope. One can easily determine whether an antibody binds to the same epitope as, or competes for binding with, a reference antibody by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope as a reference antibody, the reference antibody is allowed to bind to the target molecule under494903-1524-0106, v. 1saturating conditions. Next, the ability of a test antibody to bind to the target molecule is assessed. If the test antibody is able to bind to the target molecule following saturation binding with the reference antibody, it can be concluded that the test antibody binds to a different epitope than the reference antibody. On the other hand, if the test antibody is not able to bind to the target molecule following saturation binding with the reference antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference antibody.

[0170] To determine if a test antibody competes for binding with a disclosed antibody, the above-described binding methodology is performed in two orientations: In a first orientation, the disclosed antibody is allowed to bind to PSMA under saturating conditions followed by assessment of binding of the test antibody to PSMA. In a second orientation, the test antibody is allowed to bind to PSMA under saturating conditions followed by assessment of binding of the disclosed antibody to PSMA, If, in both orientations, only the first (saturating) antibody is capable of binding to PSMA, then it is concluded that the test antibody and the disclosed antibody compete for binding to PSMA. As will be appreciated by a person of ordinary skill in the art, a test antibody that competes for binding with a disclosed antibody may not necessarily bind to the identical epitope as the disclosed antibody, but may sterically block binding of the disclosed antibody by binding an overlapping or adjacent epitope.

[0171] Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a l-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90%, or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990 50:1495-1502). Alternatively, two antibodies⁻¹ave the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies⁻¹ave overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0172] Additional routine experimentation (e.g., peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.504903-1524-0106, v. 1

[0173] The antibodies may be defined by their variable sequence, which include additional “framework” regions. Furthermore, the antibodies sequences may vary from these sequences, optionally using methods discussed in greater detail below. For example, nucleic acid sequences may vary from those set out above in that (a) the variable regions may be segregated away from the constant domains of the light and heavy chains, (b) the nucleic acids may vary from those set out above while not affecting the residues encoded thereby, (c) the nucleic acids may vary from those set out above by a given percentage, e.g, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology, (d) the nucleic acids may vary from those set out above by virtue of the ability to hybridize under high stringency conditions, as exemplified by low salt and / or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C, (e) the amino acids may vary from those set out above by a given percentage, e.g, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology, or (f) the amino acids may vary from those set out above by permitting conservative substitutions.

[0174] When comparing polynucleotide and polypeptide sequences, two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[0175] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection.514903-1524-0106, v. 1

[0176] One particular example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2,0 algorithms, which are described in Altschul etal. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul etal. (1990) J, Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2,0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the disclosure. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. The rearranged nature of an antibody sequence and the variable length of each gene requires multiple rounds of BLAST searches for a single antibody sequence. Also, manual assembly of different genes is difficult and error-prone. The sequence analysis tool IgBLAST (world-wide-web at ncbi.nlm.nih.gov / igblast / ) identifies matches to the germline V, D and J genes, details at rearrangement junctions, the delineation of Ig V domain framework regions and complementarity determining regions, IgBLAST can analyze nucleotide or protein sequences and can process sequences in batches and allows searches against the gemiline gene databases and other sequence databases simultaneously to minimize the chance of missing possibly the best matching germline V gene.

[0177] By “germline nucleic acid residue” is meant the nucleic acid residue that naturally occurs in a germline gene encoding a constant or variable region. “Germline gene” is the DNA found in a germ cell (i.e., a cell destined to become an egg or in the sperm), A “germline mutation” refers to a heritable change in a particular DNA that has occurred in a germ cell or the zygote at the single-cell stage, and when transmitted to offspring, such a mutation is incorporated in every cell of the body. A gemiline mutation is in contrast to a somatic mutation which is acquired in a single body cell. In some cases, nucleotides in a germline DNA sequence encoding for a variable region are mutated i.e., a somatic mutation) and replaced with a different nucleotide.

[0178] In one approach, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid524903-1524-0106, v. 1residues occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[0179] Yet another way of defining an antibody is as a “derivative” of any of the antibodies provided herein and their antigen-binding fragments. A derivative antibody or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. An antibody derivative may possess a similar or identical function as the parental antibody. An antibody derivative may exhibit an altered activity relative to the parental antibody. For example, a derivative antibody (or fragment thereof) can bind to its epitope more tightly or be more resistant to proteolysis than the parental antibody.

[0180] The term “derivative” refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to an antigen but which comprises, one, two, three, four, five or more amino acid substitutions, additions, deletions or modifications relative to a “parental” (or wild-type) molecule. Such amino acid substitutions or additions may introduce naturally occurring (i.e., DNA-encoded) or non-naturally occurring amino acid residues. The term “derivative” encompasses, for example, as variants⁻¹aving altered CHI, hinge, Cn2, CH3 or CH4 regions, so as to form, for example antibodies, etc., having variant Fc regions that exhibit enhanced or impaired effector or binding characteristics. The term “derivative” additionally encompasses non-amino acid modifications, for example, amino acids that may be glycosylated (e.g., have altered mannose, 2-N-acetylglucosamine, galactose, fucose, glucose, sialic acid, 5-N-acetylneuraminic acid, 5-glycolneuraminic acid, etc. content), acetylated, pegylated, phosphorylated, amidated, derivatized by known protecting / blocking groups, proteolytic cleavage, linked to a cellular ligand or other protein, etc. The altered carbohydrate modifications maymodulate one or more of the following: solubilization of the antibody, facilitation of subcellular transport and secretion of the antibody, promotion of antibody assembly, conformational integrity, and antibody-mediated effector function. The altered carbohydrate modifications may enhance antibody mediated effector function relative to the antibody lacking the carbohydrate modification. Carbohydrate modifications that lead to altered antibody mediated effector function are well known in the art.534903-1524-0106, v. 1

[0181] A derivative antibody or antibody fragment can be generated with an engineered sequence or glycosylation state to confer preferred levels of activity in antibody dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibodydependent neutrophil phagocytosis (ADNP), or antibody-dependent complement deposition (ADCD) functions as measured by bead-based or cell-based assays or in vivo studies in animal models.

[0182] A derivative antibody or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. An antibody derivative may possess a similar or identical function as the parental antibody. An antibody derivative may exhibit an altered activity relative to the parental antibody. For example, a derivative antibody (or fragment thereof) can bind to its epitope more tightly or be more resistant to proteolysis than the parental antibody.

[0183] One can determine the biophysical properties of antibodies. One can use elevated temperature to unfold antibodies to determine relative stability, using average apparent melting temperatures. Differential Scanning Calorimetry (DSC) measures the heat capacity, Cp, of a molecule (the heat required to warm it, per degree) as a function of temperature. One can use DSC to study the thermal stability of antibodies. DSC data for mAbs is particularly interesting because it sometimes resolves the unfolding of individual domains within the mAb structure, producing up to three peaks in the thermogram (from unfolding of the Fab, CH2, and CH3 domains). Typically unfolding of the Fab domain produces the strongest peak. The DSC profiles and relati ve stability of the Fc portion show characteristic differences for the human IgG1, IgG2, IgG3, and IgG4 subclasses (Garber and Demarest, Biochem. Biophys. Res. Commun. 355, 751-757, 2007). One also can determine average apparent melting temperature using circular dichroism (CD), performed with a CD spectrometer. Far-UV CD spectra will be measured for antibodies in the range of 200 to 260 nm at increments of 0.5 nm. The final spectra can be determined as averages of 20 accumulations. Residue ellipticity values can be calculated after background subtraction. Thermal unfolding of antibodies (0.1 mg / mL) can be monitored at 235 nm from 25-95 °C and a heating rate of 1 °C / min. One can use dynamic light scattering (DLS) to assess for propensity for aggregation. DLS is used to characterize size of various particles including proteins. If the system is not disperse in size, the mean effective diameter of the particles can be determined. This measurement depends on the size of the544903-1524-0106, v. 1particle core, the size of surface structures, and particle concentration. Since DLS essentially measures fluctuations in scattered light intensity due to particles, the diffusion coefficient of the particles can be determined. DLS software in commercial DLS instruments displays the particle population at different diameters. Stability studies can be done conveniently using DLS. DLS measurements of a sample can show whether the particles aggregate over time or with temperature variation by determining whether the hydrodynamic radius of the particle increases. If particles aggregate, one can see a larger population of particles with a larger radius. Stability depending on temperature can be analyzed by controlling the temperature in situ. Capillary electrophoresis (CE) techniques include proven methodologies for determining features of antibody stability. One can use an iCE approach to resolve antibody protein charge variants due to deamidation, C -terminal lysines, sialylation, oxidation, glycosylation, and any other change to the protein that can result in a change in pl of the protein. Each of the expressed antibody proteins can be evaluated by high throughput, free solution isoelectric focusing (lEF) in a capillary column (cIEF), using a Protein Simple Maurice instalment. Whole-column UV absorption detection can be performed every 30 seconds for real time monitoring of molecules focusing at the isoelectric points (pls). This approach combines the high resolution of traditional gel IEF with the advantages of quantitation and automation found in column-based separations while eliminating the need for a mobilization step. The technique yields reproducible, quantitative analysis of identity, purity, and heterogeneity profiles for the expressed antibodies. The results identify charge heterogeneity and molecular sizing on the antibodies, with both absorbance and native fluorescence detection modes and with sensitivity of detection down to 0.7 pg / mL.

[0184] One can determine the intrinsic solubility score of antibody sequences. The intrinsic solubility scores can be calculated using CamSol Intrinsic (Somianni et al., J Mol Biol 427, 478-490, 2015). The amino acid sequences for residues 95-102 (Kabat numbering) in HCDR3 of each antibody fragment such as a scFv can be evaluated via the online program to calculate the solubility scores. One also can determine solubility using laboratory techniques. Various techniques exist, including addition of lyophilized protein to a solution until the solution becomes saturated and the solubility limit is reached, or concentration by ultrafiltration in a microconcentrator with a suitable molecular weight cut-off. The most straightforward method is induction of amorphous precipitation, which measures protein solubility using a method involving protein precipitation using ammonium sulfate (Trevino et al.,, J Mol Biol, 366: 449-460, 2007). Ammonium sulfate precipitation gives quick and accurate554903-1524-0106, v. 1information on relative solubility values. Ammonium sulfate precipitation produces precipitated solutions with well-defined aqueous and solid phases and requires relatively small amounts of protein. Solubility measurements performed using induction of amorphous precipitation by ammonium sulfate also can be done easily at different pH values. Protein solubility is⁻¹ighly pH dependent, and pH is considered the most important extrinsic factor that affects solubility.III. Pharmaceutical Formulations

[0185] The present disclosure provides pharmaceutical compositions comprising antibodies that bind to human PSMA. Such compositions comprise a prophylactically or therapeutically effective amount of an antibody or a fragment thereof and a pharmaceutically acceptable carrier.

[0186] The phrases “pharmaceutical or pharmacologically acceptable” refers to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, such as a human, as appropriate. The preparation of a pharmaceutical composition comprising an antibody or additional active ingredient will be known to those of skill in the art in light of the present disclosure. Moreover, for animal (e.g, human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biological Standards.

[0187] As used herein, “pharmaceutically acceptable carrier” includes any and all aqueous solvents (e.g, water, alcoholic / aqueous solutions, saline solutions, parenteral vehicles, such as sodium chloride, Ringer’s dextrose, etc.), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oil, and injectable organic esters, such as ethyl oleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, anti-oxidants, chelating agents, and inert gases), isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, fluid and nutrient replenishers, such like materials and combinations thereof, as would be known to one of ordinary skill in the art. Water is a particular carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. The pH and exact concentration of the various564903-1524-0106, v. 1components in a pharmaceutical composition are adjusted according to well-known parameters.

[0188] As used herein, an “antibody-drug conjugate (ADC)” includes any and all compositions where the anti-PSMA antibody is conjugated to a small-molecule (e.g., auristatins, maytansinoids, tubulysins, calicheamycins, duocarmycins, exatecans, pyrrol obenzodiazepines, TLR agonists, STING agonist) through a chemical linker.

[0189] The active ingredients can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and, the preparations can also be emulsified.

[0190] The proteinaceous compositions may be formulated into a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropyl amine, trimethylamine, histidine, procaine and the like.

[0191] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in Remington’s Pharmaceutical Sciences. Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.

[0192] Passive transfer of antibodies generally will involve the use of intravenous or intramuscular injections. The forms of antibody can be as monoclonal antibodies. The antibodies will be formulated in a carrier suitable for injection, z'.e., sterile and syringeable.574903-1524-0106, v. 1

[0193] The term “unit dose” or “dosage” refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the therapeutic composition calculated to produce the desired responses discussed above in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the effect desired. The actual dosage amount of a composition of an ADC as described herein administered to a patient or subject can be determined by physical and physiological factors, such as body weight, the age, health, and sex of the subject, the type of disease being treated, the extent of disease penetration, previous or concurrent therapeutic interventions, idiopathy of the patient, the route of administration, and the potency, stability, and toxicity of the particular therapeutic substance. For example, a dose may also comprise from about 1 pg / kg / body weight to about 1000 mg / kg / body weight (this such range includes intervening doses) or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 pg / kg / body weight to about 100 mg / kg / body weight, about 5 pg / kg / body weight to about 500 mg / kg / body weight, etc., can be administered. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.IV. Methods of Treatment

[0194] The antibodies and / or the antibody compositions provided herein can be used to treat, ameliorate, or prevent diseases, disorders, or symptoms described herein. The antibodies or the antibody compositions provided herein can be used to treat, ameliorate, or prevent diseases, disorders, or symptoms associated with cancer. The compositions and methods provided herein may involve administering an antibody or an antibody composition provided herein, optionally in combination with a second or additional therapy.

[0195] The antibodies and / or the antibody compositions provided herein may be used to treat PSMA expressing tumors, such as, for example, prostate cancer.

[0196] The subject may have been treated with a therapeutic agent targeting the disease or condition, e.g. the tumor, prior to administration of the antibody or antibody composition provided herein. The subject may be refractory or non-responsive to the other therapeutic agent.

[0197] The subject may have persistent or relapsed disease, e.g., following treatment with another therapeutic intervention, including chemotherapy, radiation, and / or hematopoietic584903-1524-0106, v. 1stem cell transplantation (HSCT), e.g., allogenic HSCT. The administration may effectively treat the subject despite the subject having become resistant to another therapy.

[0198] The subject may be responsive to the other therapeutic agent, and treatment with the therapeutic agent reduces disease burden. The subject may be initially responsive to the therapeutic agent, but exhibits a relapse of the disease or condition over time. The subject may have not relapsed. The subject may be determined to be at risk for relapse, such as at a high risk of relapse, and thus the antibody is administered prophylactically, e.g., to reduce the likelihood of or prevent relapse. The subj ect may not have received prior treatment with another therapeutic agent.

[0199] The antibody disclosed in the present invention can be administered to an animal, preferably a mammal, even more preferably a human, to treat a cancer. In addition, the antibody of the present invention can be used for the treatment of any condition related to a cancer, especially a cell-mediated immune response against a tumor cell(s), where it is desirable to treat or alleviate the disease. The types of cancers to be treated with the antibody or pharmaceutical compositions of the invention include, carcinoma, blastoma, and sarcoma, and certain leukemia or lymphoid malignancies, benign and malignant tumors, and malignancies e.g., sarcomas, carcinomas, and melanomas. Other exemplary cancers include but are not limited breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, thyroid cancer, and the li e. The cancers may be non-solid tumors (such as⁻¹ematological tumors) or solid tumors. Adult tumors / cancers and pediatric tumors / cancers are also included.

[0200] The cancer may be a solid tumor or a hematological tumor. The cancer may be a carcinoma. The cancer may be a sarcoma. The cancer may be a leukemia. The cancer may be a solid tumor.

[0201] Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. Solid tumors can be benign or malignant. Different types of solid tumors are named for the type of cells that form them (such as sarcomas, carcinomas, and lymphomas). Examples of solid tumors, such as sarcomas and carcinomas, include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,594903-1524-0106, v. 1lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers, ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, Wilms' tumor, cervical cancer, testicular tumor, seminoma, bladder carcinoma, melanoma, and CNS tumors (such as a glioma (such as brainstem glioma and mixed gliomas), glioblastoma (also known as glioblastoma multiforme) astrocytoma, CNS lymphoma, germinoma, medulloblastoma, Schwannoma craniopharyogioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblastoma, retinoblastoma and brain metastases).

[0202] Carcinomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (various tissues), bladder carcinoma, including transitional cell carcinoma (a malignant neoplasm of the bladder), bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelial carcinoma, and nasopharyngeal carcinoma.

[0203] Sarcomas that can be amenable to therapy by a method disclosed herein include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.

[0204] “Treatment” and “treating” refer to administration or application of a therapeutic agent to a subject or performance of a procedure or modality on a subject for the purpose of obtaining a therapeutic benefit of a disease or health-related condition. For example,604903-1524-0106, v. 1a treatment may include administration of a pharmaceutically effective amount of at least one antibody that targets PSM A, either alone or in combination with other therapies.

[0205] The term “subject” as used herein refers to any individual or patient to which the subject methods are performed. Generally, the subject is⁻¹uman, although as will be appreciated by those in the art, the subject may be an animal. Thus, other animals, including mammals, such as rodents (including mice, rats, hamsters, and guinea pigs), cats, dogs, rabbits, farm animals (including cows, horses, goats, sheep, pigs, e / c.), and primates (including monkeys, chimpanzees, orangutans, and gorillas) are included within the definition of subject.

[0206] The term “therapeutic benefit” or “therapeutically effective” as used throughout this application refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease. For example, treatment of caner may involve, for example, complete or partial remission.

[0207] In addition to being used as a monotherapy, the antibodies of the present invention may also find use in combination therapies. Effective combination therapy may be achieved with a single composition or pharmacological formulation that includes both agents, or with two distinct compositions or formulations, administered at the same time, wherein one composition includes at least one antibody of this invention, and the other includes the second agent(s). Alternatively, the antibody therapy may precede or follow the other agent treatment by intervals ranging from minutes to months.

[0208] Various combinations may be employed, such as when an antibody of the present invention is “A” and “B” represents a secondary' agent, non-limiting examples of which are described below:A / B / A B / A / B B / B / A A / A / B A / B / B B / A / A A / B / B / B B / A / B / BB / B / B / A B / B / A / B A / A / B / B A / B / A / B A / B / B / A B / B / A / AB / A / B / A B / A / A / B A / A / A / B B / A / A / A A / B / A / A A / A / B / A

[0209] The anti-PSMA antibody may be administered to the subject in a series of treatments. The anti-PSMA antibody and a second treatment may be administered in any order or concurrently. The anti-PSMA antibody may be administered to patients that have previously undergone treatment with the second treatment. The anti-PSMA antibody and the second614903-1524-0106, v. 1treatment may be administered substantially simultaneously or concurrently. For example, a subject may be given the anti-PSMA antibody while undergoing a course of treatment with the second treatment. The anti-PSMA antibody may be administered within 1 year of the treatment with the second treatment. The anti-PSMA antibody may be administered within 10, 8, 6, 4, or 2 months of any treatment with the second treatment. The anti-PSMA antibody may be administered within 4, 3, 2, or 1 week of any treatment with the second treatment. The anti- PSMA antibody may be administered within 5, 4, 3, 2, or 1 days of any treatment with the second treatment. The two treatments may be administered to the subject within a matter of hours or minutes (i.e., simultaneously).

[0210] The subject may be provided a secondary treatment. Secondary' treatments include but are not limited to chemotherapy, radiation, surgery, and medications.

[0211] The second treatment may comprise another antibody. Thus, treatment can involve the combined administration of antibodies provided herein with other antibodies against additional antigens, such as, but not limited to PD-1 antagonist or anti-CTLA-4 antibody or antigen binding fragment thereof. The second treatment may comprise a biotherapeutic agent including but not limited to antibodies to VEGF, EGFR, Her / neu, VEGF receptor, other growth factors, CD20, CD40, CD-40L, OX-40, 4-1BB and ICOS. Combined administration can include co-admini strati on, either in a single pharmaceutical formulation or using separate formulations, or consecutive administration in either order but generally within a time period such that all active agents can exert their biological activities simultaneously.V. Kits

[0212] Also provided herein are kits containing therapeutic agents and / or other therapeutic and delivery' agents. A kit may be provided for preparing and / or administering a therapy as described herein. The kit may comprise one or more sealed vials containing any of the pharmaceutical compositions described herein. The kit may include, for example, at least one ADC, as well as reagents to prepare, formulate, and / or administer the components of the compositions provided herein or perform one or more steps of the methods provided herein. The kit may also comprise a suitable container, which is a container that will not react with components of the kit, such as an eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made from sterilizable materials such as plastic or glass.624903-1524-0106, v. 1

[0213] Also provided are immunodetection kits for use with the immunodetection methods described above. As the antibodies may be used to detect PS A, the antibodies may be included in the kit. The immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to PSMA, and optionally an immunodetection reagent.

[0214] The kit may further include an instruction sheet that outlines the procedural steps of the methods set forth herein, and will follow substantially the same procedures as described herein or are known to those of ordinary skill in the art. The instruction information may be in a computer readable media containing machine-readable instructions that, when executed using a computer, cause the display of a real or virtual procedure of delivering a pharmaceutically effective amount of a therapeutic agent.VI. Examples

[0215] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.Example 1

[0216] As small-molecule drug conjugation levels are correlated with the numbers of fused CD38 for ARC-ADCs, the inventors envisioned that genetic additions of CD38 to the C-termini of antibody heavy and light chains in a tandem fashion may afford IgG fusions with more enzymatically active CD38 and little reduction in antigen-binding affinity, facilitating the production of ADCs with higher DARs. To this end, an anti-human PSMA monoclonal antibody (clone: J591) was chosen as a model to create IgG-CD38 fusions and ARC-ADCs (Chang, et al., 1999). Heavy and light chains of the anti-PSMA IgG were genetically fused with single and dual tandem CD38 catalytic domains at C -termini. Flexible GGGGS (SEQ ID NO: 18) linkers were used to separate the antibody and CD38 domain as well as two consecutive CD38 molecules. Mammalian expression vectors encoding anti-PSMA IgG heavy chains (HCs) generated without and with single and dual CD38 were combined with ones634903-1524-0106, v. 1expressing anti-PSMA IgG light chains (LCs) without and with single and dual CD38 for transient transfection of Expi293F cells. Expressed IgG and IgG-CD38 fusions were purified through protein G affinity chromatography and analyzed by SDS-PAGE gels stained with Coomassie Brilliant Blue (FIG. IB). In contrast to the anti-PSMA IgG featuring light and heavy chains around 23 and 49 kDa, respectively, generated anti-PSMA IgG-CD38 fusions revealed correspondingly increased molecular weights for heavy and light chains, consistent with molecular designs. For example, the anti-PSMA IgG with HC-CD38 and LC-CD38 fusions (IgG-4CD38-S) were characterized by upshifts of ~29 kDa for both HC and LC relative to those of the anti-PSMA IgG, whereas the anti-PSMA IgG with HC-CD38-CD38 fusion (IgG-4CD38-D) showed a HC migrating at over 100 kDa and a LC remaining at 23 kDa. The anti- PSMA IgG with HC-CD38-CD38 and LC-CD38-CD38 fusions (IgG-8CD38) features a HC and LC above 100 and 80 kDa, respectively. The yields are approximately 8.5 mg L'1for IgG with HC-CD38 fusion (IgG-2CD38), 5 mg L.'1for IgG-4CD38-S, 2.5 mg L1for IgG-4CD38-D, 2 mg L‘lfor IgG with HC-CD38-CD38 and LC-CD38 fusions (IgG-6CD38), and 0.6 mg L‘1for IgG-8CD38, lower than that of anti-PSMA IgG (10 mg L’1). Furthermore, based on the aggregation tendency and thermostability results, all anti-PSMA IgG-CD38 constructs showed similar stability (FIGS. 8 and 9), compared with native anti-PSMA antibody. These results demonstrate that anti-PSMA IgG fusions with varied numbers of CD38 in single and dual tandem format can be stably expressed.

[0217] The enzymatic activities of fused CD38 were then examined using a nicotinamide guanine dinucleotide (NGD+)-based fluorescence assay (Dai, et al., 2018; Kao, et al., 2024). In addition to NAD+, CD38 can recognize NGD+ as substrate and catalyze formation of fluorescent cyclic GDP-ribose (cGDPR) (Graeff, et al., 1994) Like recombinant CD38 extracellular domain, all anti-PSMA IgG-CD38 fusion proteins display robust catalytic activities with NGD’ based on increases in fluorescence intensity (FIG. 2A). As controls, reactions with the anti-PSMA IgG revealed no significant changes in fluorescence signals. The levels of enzymatic activities for IgG-4CD38-S and IgG-4CD38-D fusion proteins are comparable. They are higher than those of recombinant CD38 and IgG-2CD38 proteins but lower in comparison with those of IgG-6CD38 and IgG-8CD38 fusions under the same molar concentration. These results suggest that the single and dual tandem CD38 domains within these anti-PSMA IgG-CD38 fusions are catalytically active for subsequent drug conjugations.644903-1524-0106, v. 1

[0218] Binding to recombinant human PSMA antigens was then analyzed by ELISA for the IgG-CD38 fusion proteins. Anti -PSMA IgG-2CD38, IgG-4CD38-S, IgG-4CD38-D, and IgG-6CD38 fusions exhibit tight binding to PSMA, comparable to that of native anti-PSMA IgG (EC50: 1.05 ± 0.52 nM) (FIG. 2B). In contrast, anti-PSMA IgG-8CD38 fusion protein shows lower affinity. No binding to PSMA was observed for recombinant CD38 enzymatic domain. Furthermore, binding specificity was studied using prostate cancer cell lines LNCaP (PSMA+), C4-2B (PSMA+), and DU145 (PSMA-) (FIG. 2C). Flow cytometric analysis indicated that anti-PSMA IgG along with the generated IgG-CD38 fusions can tightly bind to LNCaP and C4-2B cells, but not DU145 cells (FIG. 2D). No binding to these cell lines was observed under the same conditions for recombinant CD38 enzymatic domain (FIG. 2E). Taken together, these results support successful generation of IgG fusion proteins with enzymatically active CD38 molecules as well as⁻¹igh affinity and specificity for human PSMA.

[0219] To generate anti-PSMA ARC-ADCs, MMAF, a tubulin inhibitor with highly potent cytotoxicity for prostate tumors, was selected as the payload. Using established procedures (Dai, et al., 2020; Dai, et al., 2021; Zhang, et al., 2024; Zhang, et al., 2022; Stephens, et al., 2023), the drug-linker conjugate 2'-Cl-araNAD+-MMAF was prepared (FIG.1A). Anti-PSMA ARC-ADCs were synthesized through one-step reactions by incubating anti-PSMA IgG-CD38 fusions with the 2'-Cl-araNAD+-MMAF on ice overnight. No residual enzymatic activities of the IgG-CD38 fusions were detected at the completion of conjugations using NGD+-based fluorescence assays. Mass spectrometric analysis of the resulting ADCs along with non-conjugated IgG-CD38 fusions indicated covalent attachments of 2, 4, 6, and 8 MMAF drugs to CD38-containing heavy and light chains of the IgG fusion proteins with matched numbers of CD38 molecules (FIG. 5). Flow cytometry revealed comparable binding affinity and specificity toward PSMA-positive LNCaP and C4-2B and PSMA-negative DU145 cells for anti-PSMA IgG-CD38 fusions and ARC-ADCs and no detectable binding to these prostate cancer cell lines by the CD38-MMAF conjugate (FIG. 6).

[0220] Next, in vitro cytotoxicity was evaluated for anti-PSMA ARC-ADCs with LNCaP, C4-2B, and DU145 prostate cancer cells. In contrast to free drug MMAF-alkyne with ECso values in a range of 35-105 pM for all three cell lines, the five different forms of anti- PSMA ARC-ADCs with defined DARs of 2, 4, 6, and 8 can potently kill PSMA-expressing LNCaP and C4-2B cells (EC50 range: 0.6-35 pM) and display little cytotoxicity against DU145 cells (PSMA") at concentrations up to 12 nM (FIG. 3). No or weak cytotoxicity was seen for654903-1524-0106, v. 1the anti-PSMA IgG and MMAF -linker conjugate (2'-Cl-araNAD+-MMAF) with these cell lines under the same conditions. Compared with the anti-PSMA ARC-ADC with HC-CD38 fusion (DAR2-ARC ADC; ECso: 24.45 pM for LNCaP and 34.54 pM for C4-2B), other four types of ARC-ADCs with DARs of 4, 6, and 8 are more potent in killing LNCaP and C4-2B cells. The ECso of the ARC-ADC with HC-CD38 and LC-CD38 fusions (DAR4S-ARC-ADC) is 1.32 pM for LNCaP and 13.72 pM for C4-2B, similar to those of the ARC-ADC with HC-CD38-CD38 fusion (DAR4D-ARC-ADC). Notably, the ARC-ADC with HC-CD38-CD38 and LC- CD38 fusions (DAR6-ARC-ADC) features the highest potency among five constructs (EC5O: 0.68 pM for LNCaP and 6.40 pM for C4-2B). In comparison, the ARC-ADC with HC-CD38-CD38 and LC-CD38-CD38 fusions (DAR8-ARC-ADC) shows reduced or comparable cytotoxicity (EC5O: 11.04 pM for LNCaP and 7.68 pM for C4-2B). These data indicate excellent potency and specificity for the anti-PSMA ARC-ADCs.

[0221] Plasma stability for four anti-PSMA ARC-ADCs with DARs of 4, 6, and 8 was then examined in mice, given their potent cytotoxicity for PSMA-expressing prostate tumor cells. Surrogate ARC-ADCs were prepared by using fluorescein isothiocyanate (FITC) as the payloads. Following single intravenous injections, concentrations of surrogate ARC-ADCs were measured by sandwich ELISA using an anti-FITC antibody and anti-human kappa light chain antibody as capture and detection antibody, respectively. The DAR4S-ARC-ADC is characterized by a half-life of 37.4 h, slightly longer than that of DAR4D-ARC-ADC ( / 1 / 2: 28,8 h) (FIG. 4A). Half-lives were determined to be 20.8 h for DAR6-ARC-ADC and 17.9 h for DAR8- ARC- ADC.

[0222] In vivo efficacy was evaluated for anti-PSMA DAR6-ARC-ADC and DAR8-ARC-ADC using immunodeficient mice implanted with LNCaP-derived tumors. In contrast to animals treated with the vehicle phosphate-buffered saline (PBS), mice received DAR6-ARC-ADC and DAR8-ARC-ADC at 0.5 mg kg'1showed slowed tumor growth in a comparable manner (FIG. 4B). Notably, treatment by DAR6-ARC-ADC at 5 mg kg'1leads to significant tumor suppression in mice. In comparison to 26-day median survival for the PBS-treated group, the median survival was increased by 27% (33 day) and 96% (51 day) for mice receiving DAR6-ARC-ADCs at 0.5 and 5 mg kg'1, respectively, and 15% (30 day) for ones treated by DAR8-ARC-ADC at 0.5 mg kg'1(FIG. 4C). Animals across all groups revealed no loss of body weight during the efficacy study (FIG. 4D). In addition, no significant changes in plasma ALT activity and creatinine concentration and major organ weight were observed for any of the664903-1524-0106, v. 1groups (FIGS. 4E, 4D, and 7). Collectively, these results support efficacy and safety of the anti PSMA ARC-ADCs in a mouse xenograft model of prostate cancer.Example 2 - Materials and Methods

[0223] Materials. EcoRI-HF (R3101S) and NheI-HF (R3131S) restriction enzymes and 1'4 DNA ligase (M0202S) for molecular cloning were ordered from New England Biolabs (Ipswich, MA). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (M6494), goat anti-human kappa light chain secondary antibody, horseradish peroxidase (HRP) (A18853), mouse anti-His6 monoclonal antibody (MAI-21315), goat anti-mouse IgG Fc secondary' antibody, HRP (A 16084), QuantaBlu fluorogenic peroxidase substrate kits (15169), and HisPur Ni-NTA resin (88221) were obtained from Thermo Fisher Scientific (Waltham, MA). Dulbecco’s PBS (DPBS) (45000-436), protein G resin (76510-280), RPMI 1640 medium (45000-396), Dulbecco’s modified Eagle’s medium (DMEM) (45000-312), and Matrigel basement membrane matrix (47747-220) were purchased from VWR (Radnor, PA). Nicotinamide guanine dinucleotide sodium salt (NGD+) (N5131), bovine serum albumin (BSA) (12659-25GM), and Amicon centrifugal filters (UFC901008 and UFC903008) were ordered from Sigma-Aldrich (St. Louis, MO). DBCO-PEG3-FITC probe (CP-4016) was purchased from Conju-Probe (San Diego, CA).

[0224] Chemical synthesis. 2'-Cl-araNAD+-N3, MMAF-alkyne, and 2'-Cl-araNAD+-MMAF were synthesized according to published procedures (Dai, et al., 2020; Dai, et al., 2021).

[0225] Molecular cloning of expression vectors. Synthetic DNA fragments encoding light chain (LC) and heavy chain (HC) of the fragment antigen-binding region (Fab) of an antihuman PSMA antibody (clone: J591) were purchased from Integrated DNA Technologies (LA, US A). The DN A fragment of the anti-human PSMA IgG LC was amplified via polymerase chain reaction (PCR) with primers incorporating DNA restriction enzyme cleavage sites for EcoRI and Nhel at the 5'- and 3 '-ends, respectively. Full-length anti -human PSMA IgG HC was generated through overlap extension PCR using the anti-human PSMA Fab HC and human IgGl Fc fragments as templates and primers containing DNA restriction enzyme cleavage sites for EcoRI and Nhel at the 5'- and 3 '-ends, respectively. Amplified DNA fragments were purified and processed by restriction enzymes EcoRI and Nhel (New England Biolabs, MA)674903-1524-0106, v. 1and ligated into the pFUSE vector backbone by DNA T4 ligase (New England Biolabs, MA) to produce expression constructs for anti-PSMA IgG LC and HC.

[0226] To construct pFUSE expression vectors of anti-PSMA IgG LC-CD38 and HC-CD38 fusions, DNA fragments for anti -human PSMA IgG LC and HC and the extracellular domain of human CD38 (R45-I300) with four mutated asparagine residues (N100D, N164A, N129D, and N209D) were amplified separately, followed by overlap extension PCR. A flexible GGGGS (SEQ ID NO: 18) linker was placed at N-terminus of CD38. PCR products were then analyzed by DNA gels and purified using DNA gel extraction kits (Zymo Research, CA, USA). Following treatment with DNA restriction enzymes EcoRI and Nhel and ligation into the pFUSE vectors by T4 DNA ligase, plasmids expressing anti-PSMA IgG LC and HC with single CD38 fusions were created.

[0227] DNA fragments of anti-PSMA IgG LC-CD38-CD38 and HC-CD38-CD38 fusions were generated by overlap extension PCR using separately amplified fragments of anti-PSMA IgGLC-CD38, HC-CD38, and human CD38 extracellular domain. A flexible GGGGS (SEQ ID NO: 18) linker was added between CD38 molecules. After digestion by EcoRI and Nhel enzymes, PCR products were ligated into pFUSE vectors by T4 DNA ligase to generate anti-PSMA IgG LC and HC expression constructs with dual CD38 fusions. All constructed pFUSE expression vectors were confirmed by DNA sequencing.

[0228] Protein expression and purification. Expi293F cells (Thermo Fisher Scientific) were utilized to express the recombinant human CD38 extracellular domain, anti-PSMA IgG, and anti-PSMA IgG-CD38 fusions, Expi293F cells (240 mL, 2.5 × 106cells mL-1) were transiently transfected with pFUSE expression vectors for human CD38 (240 pg) or anti- PSMA antibody LC (120 pg) combined with HC (120 pg) and grown at 37°C with 5% CO2 on a shaker (125 rpm) for 4 d. Media containing secreted CD38 extracellular domain or anti- PSMA antibodies were then collected by centrifugation.

[0229] To purify CD38 extracellular domain, media were first dialyzed overnight in 25 mM HEPES buffer (pH 7.5) with 250 mM NaCl, followed by loading onto gravity-flow columns packed with Ni-NTA resins twice. After washing with 20 column volumes (CVs) of 20 mM Tris-HCl buffer (pH 8.0) with 200 mM NaCl and 30 mM imidazole, CD38 extracellular domain was eluted by 10 CVs of 20 mM Tris-HCl buffer (pH 8.0) with 200 mM NaCl and 400684903-1524-0106, v. 1mM imidazole. Following 12-h dialysis in PBS at 4°C, CD38 protein was concentrated using 10 kDa MWCO centrifugal filters.

[0230] Media containing secreted anti-PSMA IgG and anti-PSMA IgG-CD38 fusions were loaded onto gravity-flow column packed with protein G resins. After extensive washing by PBS, IgG and IgG-CD38 fusions were eluted with 100 mM glycine (pH 2.7) and immediately neutralized by 1 M Tris-HCl buffer (pH 8.0). / After concentration using 30 kDa MWCO centrifugal filters, antibody concentrations were determined by UV absorbance at 280 nm and calculated molar extinction coefficients. Purified CD38 and anti-PSMA IgG and IgG fusion proteins were examined by SDS-PAGE gels stained with Coomassie Brilliant Blue.

[0231] Thermal shift assays. The thermal stability of each Anti-PSMA IgG CDS 8 fusions was detected as reported previously (Yu et al., 2024). Briefly, Each anti-PSMA IgG protein sample (5-10 pg) was diluted in PBS. Followed by adding 40× SYPRO Orange, samples were incubated in the dark for 15 minutes and detected via using a QIAGEN’s real-time PCR cycler, Rotor-Gene Q (Qiagen. Inc, USA) to be heated over a temperature range of 25°C - 95°C with a ramp rate of 0.2°C s⁻¹ The excitation and the emission wavelengths were 365 nm and 460 nm, respectively. Data was analyzed using the Rotor-Gene Q software series to calculate melting temperature (Tm).

[0232] Gel filtration chromatography. Each anti-PSMA IgG (150 pg) was loaded onto a Superdex 200 Increase 10 / 300 GL column (GE Healthcare Life Sciences, Pittsburgh, PA). Each sample was eluted with PBS buffer (0.5 mL min"1). The area under curve (AUC) of peaks were quantified to calculate the percentage of indicated peaks in F IG. 8.

[0233] Catalytic activity of CD38 extracellular domain and anti-PSMA IgG-CD38 fusions. Purified CD38 extracellular domain (20 nM), anti-PSMA IgG (10 nM), or anti-PSMA IgG-CD38 fusions (10 nM) were incubated with NGD+(100 pM) in PBS. The formation of cyclic guanosine diphosphate ribose (cGDPR) was recorded based fluorescence at 410 nm (excitation: 300 nm) using a Synergy Hl plate reader (BioTek, VT).

[0234] Binding to recombinant human PSMA by ELISA. Recombinant human PSMA protein (0.5 pg mL'1in 100 pL PBS, ACROBiosystems, Newark, DE) was coated overnight in 96-well ELISA plates at 4°C, followed by three washes with PBST (PBS with 0.05% Tween- 20) and subsequent 2-h blocking with 3% BSA in PBS at room temperature. Following three washes with PBST, purified CD38 extracellular domain, anti-PSMA IgG, or anti-PSMA IgG-694903-1524-0106, v. 1CD38 fusions in the blocking buffer at various concentrations were added for 2-h incubation at room temperature. After three washes using PBST, mouse anti-His6 antibody (0.5 pg ml.;1) for CD38 extracellular domain or goat anti -human kappa light chain secondary’ antibody, HRP (0.25 pg ml;1) for anti-PSMA IgG- or IgG-CD38 fusion was added for 1-h incubation at room temperature. After three washes of wells containing CD38 extracellular domain by PBST, goat anti-mouse IgGFc secondary antibody, HRP (0.25 pg niL’1) was added for 1-h incubation at room temperature. Plates with CD38 extracellular domains or anti-PSMA IgG or IgG-CD38 fusions were then washed three times by PBST, followed by additions of QuantaBlu fluorogenic substrate. Fluorescence signals (Ex325nm and Em410nm) were recorded by a Synergy Hl plate reader.

[0235] Synthesis of anti-PSMA ARC-ADCs and surrogates. Purified anti-PSMA IgG-CD38 fusions and recombinant CD38 extracellular domain were mixed with 2'-Cl-araNAD+-MMAF in 50 mM Tris-HCl buffer (pH 8.5) (molar ratio of protein:2'-Cl-araNAD+-MMAF: 1:50) and incubated overnight on ice. Conjugation reactions were monitored by measuring residual ADP-ribosyl cyclase activities via NGD+-based fluorescence assays as described above. Once completed, anti-PSMA ARC-ADCs and CD38-MMAF conjugates were exchanged into PBS using 30 or 10 kDa MWCO centrifugal filters, respectively, to remove the free drug-linker conjugate.

[0236] To synthesize ARC-ADC surrogates with FITC as the payload, 2' -Cl-araNAD+-N3 was conjugated with IgG-4CD38-S, IgG-4CD38-D, IgG-6CD38, and IgG-8CD38 using the same approach described above. After removal of the free 2' -Cl-araNAD+-N3 via PBS exchange, the resulting fusion antibody-linker conjugates were incubated for 30 min on ice with DBCO-PEG3-FITC in PBS (molar ratio of fusion antibody-linker conjugate: fluorescent dye: 1:50). Free dye was removed by PBS exchange.

[0237] Mass spectrometry of anti-PSMA IgG-CD38 fusions and ARC-ADCs. LC and HC of anti-PSMA IgG-CD38 fusions and ARC-ADCs were analyzed by liquid chromatography-mass spectrometry (LC-MS) using a previously published method (Dai, et al., 2020).

[0238] Flow cytometry. LNCaP, C4-2B, and DU 145 cells used for flow cytometric analysis were at passage 5 with 70% confluency. To analyze PSMA expression levels, LNCaP, C4-2B, and DU145 cells were resuspended in DPBS containing PE anti-hPSMA (2 pg ml.;1,704903-1524-0106, v. 1clone: LNI-17, BioLegend), incubated at 4°C for 30 min, and washed with DPBS. Cells without treatment were included as controls.

[0239] To evaluate binding of anti-PSMA IgG, IgG-CD38 fusions, and ARC-ADCs to LNCaP, C4-2B, and DU 145 cells, prostate cancer cells were resuspended in DPBS containing anti-PSMA IgG, IgG-CD38 fusions, or ARC-ADCs (2 pg mL’1), incubated at 4°C for 30 min, and washed with DPBS. Cells were then resuspended in ice-cold DPBS with goat anti-human IgG (H+L) cross-adsorbed secondary antibody with Alexa Fluor 647 (4 pg mL’1, Thermo Fisher Scientific), incubated at 4°C for 30 min, and washed with DPBS.

[0240] To detect binding of recombinant CD38 and CD38-MMAF conjugate to human LNCaP, C4-2B, and DU145 cells, prostate cancer cells were resuspended in DPBS containing recombinant CD38 or CD38-MMAF conjugate (2 pg mL'1), incubated at 4°C for 30 min, and washed with DPBS. Following 1-h incubation with mouse anti-His6 antibody (4 pg mL'1, clone: HIS. H8), cells were resuspended in ice-cold DPBS with goat anti-mouse IgG (H+L) cross-adsorbed secondary antibody with Alexa Fluor 647 (4 pg mL'1), incubated at 4°C for 30 min, and washed three times with DPBS.

[0241] The above stained cells were then resuspended in DPBS for flow cytometric analysis using a BD Fortessa X20 cell analyzer (BD Biosciences, CA). Cells treated only with secondary antibodies were included as controls.

[0242] In vitro cytotoxicity of anti-PSMA ARC-ADCs. LNCaP, C4-2B, and DU145 cells were seeded in 96-well plates with each well containing 5,000 cells with penicillin¬ streptomycin and incubated overnight at 37°C with 5% CO2. Cells were then treated with anti- PSMA IgG, anti-PSMA ARC-ADCs, MMAF-alkyne, and 2'-Cl-araNAD+-MMAF at different concentrations. Plates were incubated at 37°C with 5% CO₂ for 72 h, followed by additions of MTT reagent. After 2-h incubation at 37°C with 5% CO2, 100 pL of lysis buffer (SDS-HC1 solution) was introduced to each well and incubated for 2 h. Absorbance was measured at 580 nm using a Synergy Hl plate reader. Cells treated with 5 pM paclitaxel and culture medium were considered as 0% and 100% viability controls, respectively. The IC50 values were determined using GraphPad Prism.

[0243] Pharmacokinetic study of anti-PSMA ARC-ADC surrogates in mice. Male CD- 1 mice (6 weeks; n = 5) received single-dose anti-PSMA ARC-ADCs with FITC as payloads (5 mg kg'1) in DPBS by tail vein injections. Tail venipuncture was then performed for blood714903-1524-0106, v. 1collection at different time points (1, 2, 6, 12, 24, 48, 72, 96, 120, 144, and 168 h). Plasma concentrations of surrogate anti-PSMA ARC-ADCs were determined by sandwich ELISAs. Standards were prepared by serially diluting surrogate anti-PSMA ARC-ADCs in mouse plasma. An anti-FITC polyclonal antibody (0.8 ug mL-1, 71-1900, Thermo Fisher Scientific) was coated onto 96-well ELISA plates for 3 h. After five washes with PBST, plates were blocked with 3% BSA for 2 h and then incubated with 100-fold diluted plasma samples for 2 h. After five washes with PBST, plates were incubated with goat anti-human kappa light chain secondary antibody, HRP (1:4000 dilution) for 1 h. Plates were then washed five times with PBST with 0.1% Tween-20, followed by additions of 80 pL of QuantaBlu fluorogenic substrate. Fluorescence intensities (Ex325 nm and Em420 nm) were measured using a Synergy Hl plate reader. Plasma concentrations of surrogate anti-PSMA ARC-ADCs were calculated by fitting to the standard curves generated from the standards prepared on the same plates. Half¬ lives were determined by non-compartmental analysis using GraphPad Prism.

[0244] In vivo efficacy of anti-PSMA ARC-ADCs. The pharmacokinetic and efficacy studies were approved by Institutional Animal Care and Use Committee of the University of Southern California. LNCaP cells (5 million cells per mouse, at passage 5) mixed with 50% Matrigel were subcutaneously implanted into the flank of male NOD.Cg-PrkdcscidIl2rgtm1Wjl / SzJ (NSG) mice (6 weeks). The tumor size was calculated as mm3= 0.5 (length) x (width)2. After tumors grew to approximately 100 mm3, animals (n = 5) received intravenous treatment of PBS or anti-PSMA ARC-ADC (0.5 or 5 mg kg-1) every other day for a total of four times through tail vein injections. Tumor sizes and body weights were measured three times per week. Mice were euthanized once the width of tumor reached 1.5 cm. Weights of collected organs including kidney, liver, lung, heart, and spleen were measured. The Kaplan-Meier survival curve for each group was analyzed by GraphPad Prism.

[0245] ALT activities and creatinine concentrations in plasma. Plasma samples collected during the in vivo efficacy study were analyzed for ALT activities and creatinine concentrations using previously established methods (Cheng, et al., 2021; Zhang, et al., 2025).

[0246] Statistical analysis. Two-tailed unpaired t tests were performed for comparison between two groups. Tumor growth curves of control and treatment groups were analyzed using two-tailed unpaired t tests. Significance of finding was defined as follows: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. All data are shown as mean ± SD. All statistical analyses were performed using GraphPad Prism.724903-1524-0106, v. 1* * *

[0247] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.4903-1524-0106, v. 1REFERENCESThe following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.Axup et al., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 16101-16106.Beck et al., Strategies and challenges for the next generation of antibody-drug conjugates. Nat.Rev. Drug Discov. 2017, 16, 315-337.Beerli et al., Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated AntibodyDrug Conjugates with High In Vitro and In Vivo Potency. PloS ONE 2015, 10, e0131177.Bruins et al., Inducible, Site-Specific Protein Labeling by Tyrosine Oxidation-Strain-Promoted (4 + 2) Cycloaddition. Bioconjug. Chem. 2017, 28, 1189-1193,Capasso et al., A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur. J. Med. Chem. 2024, 263, 115966.Chang et al., Five different anti-prostate-specific membrane antigen (PSM / X) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999, 59, 3192-3198.Cheng et al., Expanding the toolbox of exosome-based modulators of cell functions.Biomaterials 2021, 277, 121129.Dai et al., Rational Design of a Humanized Antibody Inhibitor of Cathepsin B. Biochemistry 2020, 59, 1420-1427.Dai et al., Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. J. Control Release 2021, 336, 433-442.Dai et al., Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci.Adv. 2020, 6, eaba6752.Dai et al., Facile chemoenzymatic synthesis of a novel stable mimic of NAD(+). Chem. Sci.2018, 9, 8337-8342.Dumontet et al., Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov.2023, 22, 641-661.Fu et al., Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target Ther. 2022, 7, 93.744903-1524-0106, v. 1Graeff et al., Enzymatic synthesis and characterizations of cyclic GDP -ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J. Biol. Chem. 1994, 269, 30260-30267.Graeff et al., Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38. J. Biol. Chem. 2009, 284, 27629-27636.Hwang & Rader, Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format. Biomolecules 2020, 10, 764.Jang et al., Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther. Adv. Med. Oncol. 2023, 15, 17588359231157632.Junutula et al., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat. Biotechnol. 2008, 26, 925-932.Kao et al., Nicotinamide Riboside and CD38: Covalent Inhibition and Live-Cell Labeling.JACS Au 2024, 4, 4345-4360.Kim et al., Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases. Protein Sci. 2024, 33, e4924.Lambert & Morris, Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv. Ther. 2017, 34, 1015-1035.Li et al., Stable and Potent Selenomab-Drug Conjugates. Cell Chem. Biol. 2017, 24, 433-442 e6.Lin et al., Redox-based reagents for chemoselective methionine bioconjugation. Science 2017, 355, 597-602.Liu et al., Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998, 58, 4055-4060.Liu et al., Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38.Chem. Biol. 2008, 15, 1068-1078.Liu et al., Antibody-drug conjugates for non-oncological indications. Expert Opin. Biol. Ther.2016, 16, 591-593.Nanna et al., Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Nat. Comm. 2017, 8, 1112,Okeley et al., Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjug. Chem. 2013, 24, 1650-1655.Samantasinghar et al., A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 2023, 161, 114408.Shi et al., A poly-ADP-ribose polymer-based antibody-drug conjugate. Chem. Sci. 2020, 11,754903-1524-0106, v. 19303-9308.Stephens et al., A ribose-functionalized NAD(+) with versatile activity for ADP-ribosylation.Chem. Commun. (Camb.) 2023, 59, 13843-13846.Troyer et al., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 1995, 62, 552-558.VanBrant et al., Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjug. Chem. 2015, 26, 2249-2260.Wakankar et al., Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1:changes due to modification and conjugation processes. Bioconjug. Chem. 2010, 21, 1588-1595.Yao et al., Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov. Today 2021, 26, 1857-1874.Yu et al., Rational design of humanized antibody inhibitors for cathepsin S. Arch Biochem Biophys 2024, 751, 109849.Yurkovetskiy et al., Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect. Mol. Cancer Ther. 2021, 20, 885- 895.Zacharias et al., A homogeneous⁻¹igh-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides. Chem. Sci. 2022, 13, 3147-3160.Zhang et al., Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia. Mol. Ther. 2025, 33, 1091-1104.Zhang et al., An NAD(+) with Dually Modified Adenine for Labeling ADP-Ribosylation- Specific Proteins. Tetrahedron 2024, 168, 134361.Zhang et al., Discovery of an NAD(+) analogue with enhanced specificity for PARP1. Chem.Sci. 2022, 13, 1982-1991.Zhang et al., Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody. Angew. Chem. Int. Ed. Engl. 2015, 54, 2126-2130.Zhu et al., Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. mAbs 2014, 6, 1190-1200,764903-1524-0106, v. 1

Claims

CLAIMS1. An antibody-drug conjugate comprising:a fusion protein comprising an antibody covalently linked to six copies of an ADP-ribosyl cyclase protein via a peptide linker moiety;a 2'-modified araNAD+analogue or a 2'-modified araNMN analogue; anda payload wherein the 2'-modified araNAD+analogue or the 2'-modified araNMN analogue is conjugated to the payload to form a functionalized payload, and the functionalized payload is conjugated to the ADP-ribosyl cyclase protein,wherein the conjugate comprises a drug-to-antibody (DAR) ratio of 6:1.

2. The antibody-drug conjugate of claim 1, wherein two copies of the ADP-ribosyl cyclase protein are tandemly and covalently linked to a C -terminus of both heavy chains of the antibody and one copy of the ADP -ribosyl cyclase protein is tandemly and covalently linked to a C-terminus of both light chains of the antibody.

3. The antibody-drug conjugate of claim 1 or 2, wherein the 2'-modified araNAD+analogue comprises a chemical group at N6 of an ADP moiety of the 2'-modified araNAD+analogue, or a chemical group at C2 of an ADP moiety of the 2'-modified araNAD+analogue, wherein the chemical group optionally comprises an alkyl azide, an alkyne, BCN, or DBCO.

4. The antibody-drug conjugate of claim 3, wherein the 2'-modified araNAD+analogue comprises 2'-X-araNAD+-N₃ wherein X is fluorine, chlorine, or bromine.

5. The antibody-drug conjugate of claim 4, wherein the 2'-modified araNAD+analogue is Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI:774903-1524-0106, v. 1(I)784903-1524-0106, v. 12'-X-araNAD-N3wherein R is azido, alkyne, BCN, or DBCO;X is F, Cl, or Br; andn is 1-8.4903-1524-0106, v.

16. The antibody-drug conjugate of claim 1, wherein the 2'-modified araNMN analogue comprises 2'-X-araNMN-PO4 wherein X is fluorine, chlorine, or bromine.

7. The antibody-drug conjugate of claim 6, wherein the 2'-modified araNMN analogue is a structure selected from:wherein X is F, Cl, or Br; and n is 0-15.

8. The antibody-drug conjugate of any one of claims 1-7, wherein the payload is a chemotoxic agent or a diagnostic agent.

9. The antibody-drug conjugate of claim 8, wherein the chemotoxic agent is auristatin, calicheamicin, maytansine, duocarmycin, a camptothecin analogue or a benzodiazepine.

10. The antibody-drug conjugate of claim 9, wherein the auristatin is monomethyl auristatin F.

11. The antibody-drug conj ugate of claim 8, wherein the diagnostic agent is one or more of a fluorophore, a fluorescent protein, green fluorescence protein (GFP), a resonance energy804903-1524-0106, v. 1transfer (RET) donor molecule, a RET acceptor molecule, horseradish peroxidase (HRP), alkaline phosphatase (AP), luciferase, p-galactosidase, chloramphenicol acetyl transferase, glucose oxidase, acetate kinase, xanthine oxidase, and glucose 6-phosphate dehydrogenase.

12. The antibody-drug conjugate of any one of claims 1-11, wherein the antibody comprises a monoclonal antibody, polyclonal antibody, a single chain Fv, a bispecific antibody, a multispecific antibody, a Fv fragment, a Fab fragment, and a F(ab)? fragment.

13. The antibody-drug conjugate of any one of claims 1-12, wherein the antibody specifically binds to an antigen or epitope of a cancer cell.

14. The antibody-drug conjugate of claim 13, wherein the antigen or epitope is at least a portion of PSMA.

15. The antibody-drug conjugate of any one of claims 1-14, wherein the ADP-ribosyl cyclase protein is CD38 or BST1.

16. The antibody-drug conjugate of any one of claims 1-15, wherein the ADP-ribosyl cyclase protein comprises a full or truncated, wildtype, or mutated catalytic domain of CD38 or BST1, and the payload is conjugated to glutamate 226 of the catalytic domain of CD38 or BST1.

17. The antibody-drug conjugate of any one of claims 1-16, wherein the peptide linker moiety comprises a (GGS)npeptide (SEQ ID NOs: 23-27), (GGGS)n peptide (SEQ ID NOs: 13-17), or a (GGGGS)n peptide (SEQ ID NOs: 18-22), wherein n is an integer from 1 to 5.

18. A method of treating cancer comprising administering to a subject having cancer or suspected of having cancer a therapeutically effective amount of the antibody-drug conjugate of any one of claims 1-17, thereby inhibiting the growth of cancer cells or killing cancer cells.814903-1524-0106, v. 1